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A B S T R A C T
Background
Radiotherapy has been proposed as a treatment to prevent new vessel growth in people with neovascular age-relatedmacular degeneration
(AMD).
Objectives
The aim of this review was to examine the effects of radiotherapy on neovascular AMD.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group
Trials Register) in The Cochrane Library Issue 3, 2010, MEDLINE (January 1950 to March 2010), EMBASE (January 1980 to March
2010), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 toMarch 2010), themetaRegister
of ControlledTrials (mRCT) (www.controlled-trials.com) (March 2010) andClinicalTrials.gov (http://clinicaltrials.gov) (March 2010).
There were no language or date restrictions in the search for trials. The electronic databases were last searched on 23 March 2010. We
also wrote to investigators of trials included in the review to ask if they were aware of any other studies.
Selection criteria
We included all randomised controlled trials in which radiotherapy was compared to another treatment, sham treatment, low dosage
irradiation or no treatment in people with choroidal neovascularisation secondary to AMD.
Data collection and analysis
Two review authors independently extracted the data. We combined relative risks using a random-effects model. We estimated the
percentage of the variability in effect estimates that was due to heterogeneity, rather than sampling error, using I2.
Main results
Thirteen trials (n=1154) investigated external beam radiotherapy with dosages ranging from 7.5 to 24 Gy; one additional trial (n=
88) used plaque brachytherapy (15Gy at 1.75mm for 54 minutes/12.6 Gy at 4mm for 11 minutes). Most studies found effects (not
always significant) that favoured treatment. Overall there was a small statistically significant reduction in risk of visual acuity loss in the
treatment group. There was considerable inconsistency between trials and the trials were considered to be at risk of bias, in particular
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because of the lack of masking of treatment group. Subgroup analyses did not reveal any significant interactions, however, there were
small numbers of trials in each subgroup (range three to five). There was some indication that trials with no sham irradiation in the
control group reported a greater effect of treatment. The incidence of adverse events was low in all trials; there were no reported cases
of radiation retinopathy, optic neuropathy or malignancy. Three trials found non-significant higher rates of cataract progression in the
treatment group.
Authors’ conclusions
This review currently does not provide convincing evidence that radiotherapy is an effective treatment for neovascular AMD. If further
trials are to be considered to evaluate radiotherapy in AMD then adequate masking of the control group must be considered.
P L A I N L A N G U A G E S U M M A R Y
Radiotherapy for neovascular age-related macular degeneration
Radiotherapy (as commonly used in the treatment of cancer) has been proposed as a treatment for wet AMD as it may prevent the
growth of new vessels in the retina. This review identified 14 randomised controlled trials of radiotherapy for wet AMD. Most of these
trials showed effects (not always significant) that favoured treatment with radiotherapy to prevent vision loss. However, overall this
review does not provide convincing evidence that radiotherapy is an effective treatment for wet AMD, in part because the results of
different trials were inconsistent, but also because it is possible that the treatment effects could be explained by the fact that it was not
possible to mask the participants, and people measuring outcome, to the treatment group. The incidence of adverse effects reported in
these trials was low - nobody developed any radiation-specific side effects although in three trials higher rates of cataract were reported
in the radiotherapy group.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Radiotherapy versus control for neovascular age-related macular degeneration
Patient or population: patients with neovascular age-related macular degeneration
Settings:
Intervention: RADIATION THERAPY VERSUS CONTROL
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control RADIATION THERAPY
VERSUS CONTROL
Three or more lines vi-
sual acuity lost
Follow-up: 12 months
Medium risk population1 RR 0.90
(0.74 to 1.1)
759
(8 studies)
⊕⊕⊕©
moderate2
544 per 1000 490 per 1000
(403 to 598)
Three or more lines vi-
sual acuity lost
Follow-up: 24 months
Medium risk population1 RR 0.81
(0.63 to 1.03)
428
(4 studies)
⊕⊕©©
low3,4
757 per 1000 613 per 1000
(477 to 780)
Six or more lines visual
acuity lost
Follow-up: 12 months
Medium risk population1 RR 0.62
(0.44 to 0.87)
576
(7 studies)
⊕⊕⊕©
moderate5
342 per 1000 212 per 1000
(150 to 298)
Six or more lines visual
acuity lost
Follow-up: 24 months
Medium risk population1 RR 0.81
(0.64 to 1.03)
428
(4 studies)
⊕⊕⊕©
moderate3
444 per 1000 360 per 1000
(284 to 457)
3
R
a
d
io
th
e
ra
p
y
fo
r
n
e
o
v
a
sc
u
la
r
a
g
e
-re
la
te
d
m
a
c
u
la
r
d
e
g
e
n
e
ra
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
0
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
difference in visual acu-
ity
logMAR acuity. Scale
from: -0.2 to 2.
Follow-up: 12 months
The mean difference in vi-
sual acuity in the inter-
vention groups was
0.08 lower
(0.14 to 0.01 lower)
799
(8 studies)
⊕⊕©©
low6,7
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Median control group risk in included studies
2 Serious limitations in design: only 3 of 8 trials adequately reported sequence generation and allocation concealment; in only 3 of 8
trials were participants and outcome assessors properly masked to treatment group; in none of the trials was incomplete outcome data
properly assessed.
3 Serious limitations in design: 2 of the 4 trials adequately reported sequence generation and allocation concealment; in only 1 of the 4
trials were participants and outcome assessors properly masked to treatment group; in 1 of the 4 trials incomplete outcome data was
properly assessed.
4 Serious inconsistency: chi-sq for heterogeneity=0.04, I2=63%. Risk ratios ranged from 0.58 to 1.03. The confidence intervals for the
trials showing most extreme effects overlapped to only a small extent. Too few trials to explore this heterogeneity.
5 Serious limitations in design: only 2 of 7 trials adequately reported sequence generation and allocation concealment; in only 2 of 7
trials were participants and outcome assessors properly masked to treatment group; in none of the trials was incomplete outcome data
properly assessed.
6 Serious limitations in design: only 4 of 9 trials adequately reported sequence generation and allocation concealment; in only 4 of 9
trials were participants and outcome assessors properly masked to treatment group; in none of the trials was incomplete outcome data
properly assessed.
7 Selective outcome bias a possibility for these analyses as only some trials reported mean final visual acuity and only some trials
reported mean change in visual acuity since baseline.
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B A C K G R O U N D
Description of the condition
The macula, the central area of the retina, is used for detailed
vision such as reading, recognising faces and driving. Age-related
macular degeneration (AMD) is the leading cause of blindness
in the developed world. It is difficult to get a clear definition of
AMD. The term ’age-related’ is used partly due to its unknown
pathogenesis. It is believed that both genetic and environmental
factors play a significant role in the development of the disease.
From a clinical perspective, AMD primarily affects the macular
region. The term ’degeneration’ is used to distinguish AMD from
other genetic macular dystrophies which run in families and those
where there is a clear environmental cause such as an infection or
trauma.
There are several signs appearing in the retina that are associated
with increasing age and increased risk of developing AMD. These
signs, known as age-relatedmaculopathy (ARM), include the pres-
ence of drusen (yellow spots beneath the retina), pigmentary dis-
turbance and small focal areas of atrophy. In general, ARM is not
associated with significant visual loss. Some people with ARMwill
go on to develop AMD.
There are two types of AMD: geographic atrophy (large area of
atrophy centred in the macula) and choroidal neovascularisation
(CNV) also known as wet AMD. This review is concerned with
treatment for neovascular AMD.
In neovascular AMD, CNV develops beneath the retina. In the
initial phase the CNVmight cause visual distortion due to leakage
of fluid into the surrounding retina. At this stage the retinal func-
tion is only mildly affected and the CNV is potentially reversible.
However, the CNV may leak serum lipid and protein leading to
exudation and significant swelling of the retina. The CNV may
bleed and the haemorrhages may be toxic. Both exudation and
haemorrhages induce a scarring response. These are associatedwith
extensive damage to the architecture of the retina-retinal pigment
epithelium-choroid complex, leading to significant visual loss.
Choroidal neovascularisation is defined as classic or occult accord-
ing to its appearance on fluorescein angiography, where fluores-
cent dye is injected intravenously and imaged as it passes through
the blood vessels of the eye. Classic membranes are clearly delin-
eated and can be seen at the early frames of the angiogram. Occult
membranes present as either late leakage, which cannot be seen in
the early frames, or fibrovascular pigment epithelial detachment.
Most lesions have both classic and occult components.
Description of the intervention
Radiotherapy is commonly used in oncology and its use is increas-
ing in the treatment of non-neoplastic diseases. It is believed that
it can preferentially damage dividing and fast growing cells more
than normal supporting cells. In rats, photoreceptor cell death is
not seen at doses less than 10 Gy and the retinal pigment epithelial
cell loss does not occur under 20 Gy in single-fraction. There is
also evidence to suggest that fractionation of irradiation greatly
reduces the toxicity but preserves the DNA-damaging effects in
rapidly dividing cells.
How the intervention might work
Clinical experience suggests that cumulative doses of up to 25 Gy
cause no damage to the retina or optic nerve. As the endothelial
cells in CNV are dividing it is possible that radiotherapy can stop
the growth of CNV without significant damage to the retina.
Why it is important to do this review
There are several RCTsof radiotherapy for neovascular AMDusing
different dosage and fractionation schemes. The aim of this review
was to assess systematically the results of these studies with a view
to providing an overall estimate of treatment effect.
O B J E C T I V E S
The aim of this review was to examine the effects of radiotherapy
on neovascular AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included trials in which participants were people with CNV
secondary to AMD as defined by the study investigators.
Types of interventions
We included studies in which radiotherapy, no matter how it was
delivered, was compared to another treatment, low dosage irradi-
ation, sham treatment or no treatment.
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Types of outcome measures
Primary outcomes
The primary outcome for this review was loss of visual acuity. We
considered two measures of loss of visual acuity - 3 or more lines
lost on a logMAR chart (equivalent to doubling of visual angle
or worse) and 6 or more lines lost (equivalent to quadrupling of
visual angle or worse). We also considered mean visual acuity and
change in visual acuity as a continuous score.
Secondary outcomes
The secondary outcomes for this review were:
• measures of contrast sensitivity;
• new vessel growth;
• quality of life measures - any validated measurement scale
which aims to measure the impact of visual function loss on
quality of life of participants;
• any adverse outcomes as reported in trials.
Follow up
We measured outcomes at six, 12 and 24 months after radiation
treatment.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vi-
sion Group Trials Register) in The Cochrane Library Issue 3,
2010, MEDLINE (January 1950 to March 2010), EMBASE
(January 1980 to March 2010), Latin American and Caribbean
Health Sciences Literature Database (LILACS) (January 1982 to
March 2010), the metaRegister of Controlled Trials (mRCT) (
www.controlled-trials.com) (March 2010) and ClinicalTrials.gov
(http://clinicaltrials.gov) (March 2010). There were no language
or date restrictions in the search for trials. The electronic databases
were last searched on 23 March 2010.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), LILACS (Appendix 4), mRCT (Appendix 5) and ClinicalTri-
als.gov (Appendix 6).
Searching other resources
We contacted the investigators of the trials included in this review
for information about further trials.We searched the reference lists
of relevant studies for further trial reports. We did not perform
manual searches of conference proceedings or journals.
Data collection and analysis
Selection of studies
Two review authors independently scanned the titles and abstracts
resulting from the searches. We obtained full copies of all poten-
tially or definitely relevant articles. Two review authors assessed
the full copies according to the ’Criteria for considering studies
for this review’. We resolved disagreements by discussion.
Data extraction and management
Two review authors independently extracted data using a form
developed by the Cochrane Eyes and Vision Group. We resolved
discrepancies by discussion. In the original review, one author
entered data into RevMan 4.2 using the double data-entry facility
to check for errors. For the updates inRevMan5, datawere entered
onto a spreadsheet and cut and pasted into RevMan.
Assessment of risk of bias in included studies
Two review authors independently assessed study quality accord-
ing to methods set out in Section 6 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2006). The review
authors were not masked to any trial details during the assess-
ment. We considered four parameters of quality when grading
the articles: allocation concealment and method of allocation to
treatment; masking of providers and recipients of care; masking of
outcome assessment; and completeness of follow up. We graded
each parameter of trial quality: A - adequate; B - unclear; or C -
inadequate. We resolved disagreement between the review authors
on assessments by discussion. We contacted the trial authors for
clarification on any parameter graded B - unclear. We excluded
any trial scoring C - inadequate on allocation concealment and
method of allocation to treatment.
For the update in 2009, we used theCochrane Collaboration’s tool
for assessing the risk of bias (Higgins 2009).We assessed the extent
to which bias could have been introduced in the following aspects
of study design and execution: sequence generation, allocation
concealment, blinding (masking), incomplete outcome data and
selective outcome reporting.
Measures of treatment effect
The primary outcome of visual acuity loss was assessed at six, 12
and 24 months. We used two outcomes, loss of 3 or more lines on
a logMAR chart and loss of 6 or more lines. As the proportion of
people experiencing these outcomes was high in the control group
(more than 10%) we used the relative risk as our effect measure.
Not all trials reported visual acuity outcomes in this dichotomous
format.We contacted investigators for data but these requests were
not successful. We, therefore, also included mean visual acuity and
change in visual acuity as a continuous score.
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Unit of analysis issues
Most studies randomised participants and then studied one eye per
person. One trial (Jaakkola 2005) reported data from 88 eyes in 86
participants. As the numbers of people with both eyes erroneously
included in the analysis was small in this study, and it was not
possible to extract data for people, this error was ignored and data
on eyes used in the analysis. For one trial (Kacperek 2001) it was
not clear how the analysis was done but data could not be extracted
for the review in any case.
Dealing with missing data
Our main analyses assume that missing data is missing at random.
However, to see how reasonable this assumption might be we
also did sensitivity analyses with different assumptions about the
missing data usingmethods as set out byWhite et al (White 2008).
The “informative missingness odds ratio” (IMOR) refers to the
ratio of the odds of the outcome among participants for whom
dataweremissing and the odds of the outcome among participants
who were observed. These IMORs can be assumed to be equal or
different in the two trial arms. We did four sensitivity analyses.
Firstly we assumed the IMOR was 2 in treatment and control
groups i.e. that people who were not seen were twice as likely to
have the outcome. Secondly, we assumed that the IMOR was ½
in both treatment and control groups i.e. that people who were
not seen were half as likely to have the outcome. For the third
and fourth sensitivity analyses, we assumed that the IMOR was
opposite in treatment and control groups - i.e. 2 or ½.
All analyses were done using themetamiss command in Stata (ver-
sion 10.1, StataCorp LP, 4905 Lakeway Drive, College Station,
TX 77845 USA).
Assessment of heterogeneity
We assessed heterogeneity by looking at the forest plots to see
whether the confidence intervals for the estimates of effect over-
lapped and by looking at the χ2 and I2 value.
Assessment of reporting biases
We planned to investigate publication bias by doing a scatter plot
of the effect estimates from the individual studies against their
standard error. An asymmetric graph may indicate that smaller
studies that are not statistically significant have not been published
although it also may indicate that the effects of treatment are
different in small studies. Currently not enough trials are included
in the analyses to assess publication bias.
We investigated selective outcome reporting by doing an “outcome
matrix” and classifyingmissing outcomes according to theORBIT
classification (Kirkham 2010).
A: States outcome analysed but only reported that the treatment
differences were not statistically significant
B: States outcome analysed but only reported that treatment dif-
ferences were significant
C:Clear that outcome was analysed but insufficient data presented
to be included in meta-analysis or full tabulation
D: Clear that outcome was analysed but no results reported
E: Clear that outcome was measured (for example, includes struc-
turally related outcomes) but not necessarily analysed
F: States that outcome was not measured
G: Not mentioned but clinical judgement says likely to have been
measured
H: Not mentioned but clinical judgement says unlikely to have
been measured
I: Other give details
Data synthesis
We used a random-effects model to combine results.
There was considerable statistical heterogeneity between studies.
However, the amount of heterogeneity varied with the outcome.
We have included the pooled analyses and I2 estimates on the
graphs for information but have not reported the pooled results
in the abstract.
There were not enough data reported for other potential outcome
measures (growth of new vessels, contrast sensitivity and quality
of life) to enable a statistical analysis but these are discussed in the
results section.
Subgroup analysis and investigation of heterogeneity
Not all of the trials reported data for all outcomes. This meant
that our options for exploring the sources of heterogeneity were
limited. In our protocol we specified three factors of interest for
subgroup analyses (method of delivery, dosage and type of CNV).
All but one trial used the same method of delivery. Table 1 shows
the details of dosage in these trials. Table 2 shows the details of
CNV.
During the course of doing the review we identified one additional
aspect of study design as of interest for subgroup analysis. This
was whether or not sham irradiation was carried out in the control
group.
Using these factors we performed stratified analyses, the purpose of
which was to determine whether the outcome varied significantly
with type of explanatory variable.We used data from the 12month
follow-up and divided the trials into two groups for each factor:
high dose (more than 14 Gy) versus low dose (less than or equal to
14 Gy); 50% or more of participants with classic CNV versus less
than 50% with classic CNV; and trials with no sham irradiation
versus those with sham irradiation. As the numbers of trials were
small and the purpose of this analysis was to compare treatment
effects only, we used odds ratios pooled using a fixed-effect model.
We calculated an ’interaction effect’ (Altman 2003) i.e. compared
the pooled odds ratio in the two subgroups.
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Sensitivity analysis
Our main sensitivity analyses were regarding missing data (see
“Dealing with missing data” above).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The searches identified 149 reports. A further two potentially rel-
evant reports were identified by subsequent electronic searching
carried out for another project. We obtained full copies of 28
reports which referred to 23 potentially relevant studies. We ex-
cluded 12 of these trials largely because the treatment groups were
not randomly allocated (see ’Characteristics of excluded studies’
table). A total of 11 trials were considered suitable for inclusion
in the review (see ’Characteristics of included studies’ table). The
included studies all stated that they were RCTs but did not always
specify how they performed the randomisation (see below).
An updated search done in March 2010 identified 487 reports of
trials. After initial assessment by the Trials Search Co-ordinator,
477 references were excluded as they were deemed not relevant
to the scope of the review and the review authors subsequently
assessed ten reports. Of these ten reports, three were relevant trials
(AMDLRTSG 2003; AMDRT 2004; Jaakkola 2005), six were
ineligible trials (Avila 2009; Barak 2005;Churei 2004;Heier 2008;
Marcus 2004; Zambarakji 2006) and one was a report on quality
of life outcomes in SFRADS 2002.
Included studies
For additional information see the ’Characteristics of included
studies’ table.
Types of participants
The 14 trials randomised a total of 1242 people. The studies
took place in Germany (Anders 1998; Eter 2002; RAD 1999),
the Netherlands (Bergink 1998), Finland (Jaakkola 2005), USA
(AMDRT 2004; Char 1999; Ciulla 2002; Marcus 2001), Japan
(AMDLRTSG 2003; Kobayashi 2000), UK (Kacperek 2001;
SFRADS 2002) and Switzerland (Valmaggia 2002). In all studies
the mean age of participants was around 75 years; in most studies
the majority of participants were women, however, the percentage
female ranged from 30% to 64%.
All studies recruited participants with subfoveal CNV associated
with AMD. Most studies, with the exception of AMDLRTSG
2003, Anders 1998 and Kacperek 2001, classified the CNV lesion
as classic, occult or mixed. In most trials the percentage of partic-
ipants with classic or predominantly classic CNV ranged between
37% and 57% (Table 2). In Marcus 2001 a lower percentage of
participants with classic CNV was recruited (12%).
Two studies did not specify visual acuity criteria for entry to the
trial (Eter 2002; Valmaggia 2002). Most studies specified that eli-
gible participants should have aworst visual acuity in the study eye,
usually between 6/60 and 6/120 (AMDLRTSG 2003; AMDRT
2004; Anders 1998; Bergink 1998; Ciulla 2002; Jaakkola 2005;
Kacperek 2001; Marcus 2001; RAD 1999; SFRADS 2002); two
studies did not specify a worst acuity (Char 1999; Kobayashi
2000). Four studies specified that there should be some visual loss,
usually to 6/12 or less (Anders 1998; Char 1999; Ciulla 2002;
Kobayashi 2000).
Types of intervention
Table 1 shows the dosage of radiotherapy applied in the different
studies. Thirteen studies used external beam radiotherapy. The
dosages ranged from24Gy (four fractions of 6Gy) (Bergink 1998)
to 7.5 Gy (one fraction) (Char 1999). Only one study used plaque
brachytherapy with a dose of 12.6 Gy delivered over 11 minutes
(Jaakkola 2005).
Nine of the studies gave no treatment to the control group
(AMDLRTSG 2003; Anders 1998; Bergink 1998; Char 1999;
Eter 2002; Jaakkola 2005; Kacperek 2001; Kobayashi 2000;
SFRADS 2002); three studies used sham irradiation (Ciulla 2002;
Marcus 2001; RAD 1999) and one study used very low-dose irra-
diation (1 Gy) (Valmaggia 2002). In AMDRT 2004 some partic-
ipants in the control group received sham irradiation and others
received no treatment.
Types of outcome measures
In all studies the primary outcome was visual acuity. In most cases
this was measured using the ETDRS chart or equivalent logMAR
chart. The exception to thiswasBergink 1998where Snellen acuity
was measured. Most studies considered some aspect of the clinical
progression of CNV such as area of CNV (AMDLRTSG 2003;
AMDRT 2004; Kobayashi 2000; Valmaggia 2002) and appear-
ance of the fundus on fluorescein angiography (Jaakkola 2005;
Marcus 2001; RAD1999).Near vision (SFRADS 2002) and read-
ing ability (Valmaggia 2002) were also considered. Three studies
specifically considered safety (AMDRT 2004; Kobayashi 2000;
SFRADS 2002).
Excluded studies
See ’Characteristics of excluded studies’ table.
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Risk of bias in included studies
Figure 1 and Figure 2 summa rise the assessment of the risk of bias
in included studies.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
In four studies (Kobayashi 2000; Marcus 2001; RAD 1999;
SFRADS 2002) trial reports indicated that randomisation had
been executed properly, that is, an unpredictable sequence of treat-
ment allocation was concealed properly from people recruiting
participants into the trial.
Blinding
Studies that did not perform sham irradiation (Anders 1998;
Bergink 1998; Char 1999; Eter 2002; Kacperek 2001; Kobayashi
2000; SFRADS 2002)were at greater risk of performance biaswith
participants and providers in general being aware of the treatment
group. However, in three of these studies efforts were made to
mask the outcome assessor to treatment group (detection bias)
(Char 1999; Kobayashi 2000; SFRADS 2002).
Incomplete outcome data
Table 3; Table 4 and Table 5 summa rise the follow-up in the
included studies at six, 12 and 24 months. Follow-up rates were
not described clearly in four studies (AMDLRTSG 2003; Bergink
1998; Char 1999; Kacperek 2001). In two studies, not enough
information was given on people excluded after randomisation
(Ciulla 2002; Eter 2002) so estimates of follow-up for these stud-
ies may underestimate loss to follow-up. In one study (SFRADS
2002) a strictly intention-to-treat analysis was not performed as
one patient randomised to the control group received treatment
and was analysed in the treatment group. However, this was un-
likely to have had a major impact on the results of the study. None
of the authors included participants lost to follow up in the anal-
yses.
Appendix 7 and Appendix 8 show the sensitivity analyses making
different assumptions as to risk of outcome in people not seen.
Five different assumptions are shown:
• Missing at random (available case analysis)
• Odds of outcome in not observed twice odds of outcome in
observed in treatment and control groups
• Odds of outcome in not observed half odds of outcome in
observed in treatment and control groups
• Odds of outcome in not observed twice odds of outcome in
observed in treatment group and odds of outcome in not
observed half odds of outcome in observed in control group
• Odds of outcome in not observed half odds of outcome in
observed in treatment group and odds of outcome in not
observed twice odds of outcome in observed in control group
The pooled estimates did not appear to be at substantial risk of
bias due to missing data in the included studies (Appendix 7).
The pooled risk ratio, under various assumptions about the risk of
outcome in people who were not observed, varied on average by
less than 10% from the available case analysis. The exception to
this was loss of 6+ lines at six months where making more extreme
assumptions about outcome in people who were not seen resulted
in approximately 15%change in the pooled risk ratio. If we assume
that the odds of the outcome in people in the treatment group
who were not seen was twice that of the people who were seen,
and that the odds of the outcome in people in the control group
who were not seen was only half that of people who were seen,
the observed risk ratio showing a beneficial effect becomes non-
statistically significant.
Looking at the effect of missing data on individual studies
(Appendix 8) AMDRT 2004, Bergink 1998; Kobayashi 2000
Marcus 2001; andValmaggia 2002 all had some outcomes affected
by assumptions about missing data - in particular the assumption
that the outcome was different in non-observed participants in
treatment and control (twice the odds in treatment and half in
control). This assumption, for some outcomes, leads to a change
in risk ratio of greater than 10%.
Selective reporting
Table 6 shows the outcome reporting grid for the primary out-
come: visual acuity at six, 12 or 24 months. Visual acuity can be
presented in several different ways: loss of 3+ or 6+ lines of visual
acuity, mean visual acuity or change in visual acuity. Decisions
about which method of analysis to use can be influenced by the
statistical significance of the results and therefore this can lead to
bias. No study reported all visual acuity measures.
Effects of interventions
See: Summary of findings for the main comparison
Radiotherapy versus control for neovascular age-related macular
degeneration
Primary outcomes
Data on visual acuity were not available in a form suitable for
inclusion in the review for two studies (Eter 2002; Kacperek
2001). In Eter 2002 45 eyes of 45 participants were assigned in a
ratio of 2:1 to either radiation treatment (20 Gy in 10 fractions)
or observation. There were no statistically significant differences
between treatment and control groups six months after treatment.
InKacperek 2001 38peoplewere treatedwith radiotherapy (18Gy
in 4 fractions) and compared to 28 people who were not treated.
At 12 months visual acuity was measured on 28 participants in
the treatment group and 20 in the control group. Participants in
the control group had lost more vision than the treatment group
(Mann Whitney test P = 0.028).
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Follow up at six months
Five trials provided data on the primary outcome (3 or more lines
visual acuity lost) at six months (AMDRT 2004; Jaakkola 2005;
Marcus 2001; SFRADS 2002; Valmaggia 2002) (Analysis 1.1).
There was some inconsistency in trial results. The I2 value (per-
centage of total variation across studies that was due to heterogene-
ity rather than chance) (Higgins 2003) was 41%. The relative risk
of losing 3 or more lines six months after treatment varied from
0.40 (95% CI 0.18 to 0.88) (Valmaggia 2002) to 1.06 (95% CI
0.71 to 1.57) (Marcus 2001). There was similar inconsistency in
the outcome 6 or more lines visual acuity lost (I2 = 47%) however
all the risk ratios were in the direction of benefit varying from 0.07
(95% CI 0.0 to 1.11) (Valmaggia 2002) to 0.83 (95% CI 0.47 to
1.46) (SFRADS 2002) (Analysis 1.4).
Follow up at 12 months
Eight trials provided data on visual acuity outcomes at 12months (
AMDRT 2004; Bergink 1998; Char 1999; Jaakkola 2005;Marcus
2001; RAD 1999; SFRADS 2002; Valmaggia 2002). Again there
was inconsistency in trial results for the outcome of 3 or more lines
visual acuity lost (I2 =42%)with the relative risk varying from0.37
(95%CI 0.15 to 0.90) (Char 1999) to 1.22 (95%CI 0.91 to 1.62)
(Marcus 2001) (Analysis 1.2). There was less inconsistency for the
outcome of 6 or more lines visual acuity lost (I2 = 17%) (Analysis
1.5). Most trials provided results in the direction of benefit with
the exception of Marcus 2001 1.23 (95% CI 0.56 to 2.68). The
pooled risk ratio (random-effects model) was 0.62 (95% CI 0.44
to 0.87).
Follow up at 24 months
Four trials provided data on visual acuity outcomes at 24 months
(Jaakkola 2005; Kobayashi 2000; SFRADS 2002; Valmaggia
2002). There was considerable inconsistency in trial results for the
outcome of 3 or more lines lost (I2 = 63%) (Analysis 1.3). There
was no inconsistency in trial results for the outcome of 6 or more
lines lost (I2 = 0%) (Analysis 1.6). The random-effects pooled rel-
ative risk was 0.81 (95% CI 0.64 to 1.03). Using a fixed-effect
model the relative risk was 0.79 (95% CI 0.62 to 1.01).
Effects of missing data
Table 3; Table 4 and Table 5 show follow-up in the included
studies. The analyses presented so far assume data were missing at
random.
See Appendix 7 and Appendix 8 for sensitivity analyses and
“Incomplete outcome data” above for discussion on the effects of
missing data. With regard to the pooled analyses, we are interested
in whether our conclusions would change as a result of different
assumptions about reasons for data beingmissing. Overall, the size
and statistical significance of the effect was similar in the available
case analyses (data missing at random) and assuming that there
was a different risk of outcome in non-observed people (see table
below). There were a few exceptions to this, however the differ-
ences were still relatively small and the fact that the statistical sig-
nificance changed probably reflects the fact these were borderline
cases anyway and the upper confidence interval was close to 1 (no
effect).
Outcome Available case analysis risk ratio
(95% CI)
Assumption about missing data Risk ratio (95% CI) under this as-
sumption
3+ lines at 6 months 0.755 (0.556, 1.025) IMOR ½ 2 0.7 (0.516, 0.949)
3+ lines at 24 months 0.81 (0.636, 1.033) IMOR ½ 2 0.768 (0.593, 0.994)
6+ lines at 6 months 0.423 (0.191, 0.934) IMOR 2 ½ 0.488 (0.225, 1.055)
6+ lines at 24 months 0.811 (0.638, 1.032) IMOR ½ 2 0.741 (0.58, 0.947)
IMOR 2 ½: Odds of outcome in not observed twice odds of
outcome in observed in treatment group and odds of outcome in
not observed half odds of outcome in observed in control group.
IMOR ½ 2: Odds of outcome in not observed half odds of out-
come in observed in treatment group and odds of outcome in not
observed twice odds of outcome in observed in control group.
Visual acuity as a continuous outcome
Not all trials reported visual acuity outcomes in a dichotomous
format. In order to include data from the trials that did not, we also
collected data on logMAR visual acuity as a continuous variable.
These data were available for most trials at 12 months, either as
mean visual acuity at follow-up or change in visual acuity since
the start of the trial (Analysis 1.7). There was less heterogeneity
in these outcomes. For example, for the trials reporting change in
visual acuity, the I2 value was 15%. The pooled weighted mean
difference was -0.10 (95% CI -0.16 to -0.04). These results were
consistent with a mean change in visual acuity of 1.5 lines of visual
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acuity in favour of the treated group to approximately one third
of a line of visual acuity in favour of the treatment group.
These analyses may be at risk of selective outcome bias because
continuous data may be analysed two ways - as final visual acuity
or change in visual acuity from baseline. It is possible that the
choice of which outcome to present was influenced by the results.
Investigation of heterogeneity
With only 14 trials included in the review, and only some of these
trials providing data for some outcomes, our ability to determine
the causes of the heterogeneity or inconsistency between trials was
limited. Using the factors prespecified in the protocol (dosage and
type of CNV) and one factor not prespecified in the protocol
(sham irradiation in the control group) we performed stratified
analyses for the visual acuity outcome (3 or more lines lost) at 12
months (because this was the time period for which most data
were available) (see ’Table 7’). There were no statistically significant
interactions. There was some indication that trials with no sham
irradiation reported a greater effect of treatment as did trials with
a greater percentage of participants with classic CNV. There was
little evidence for any effect of dosage. Analysis 1.9 shows the
forest plot for the subgroup analysis by dosage with trials ordered
according to dosage (highest dosage at top and lowest dosage at
bottom of plot). There was little evidence for any trend in effect
of radiotherapy according to dosage.
Secondary outcomes
Our secondary outcome measures included change in membrane
size and contrast sensitivity. Of the trials that specifically studied
change in lesion size a beneficial outcome for treatment was found
by one (Kobayashi 2000).Nodifference in the growth rate between
treatment and controls were reported by four trials (Bergink 1998;
Char 1999; Marcus 2001; Valmaggia 2002). Of the trials that
specifically studied changes in contrast sensitivity, SFRADS 2002
reported a statistically significant difference in the loss of 0.3 log
units of contrast sensitivity in favour of treatment at 24months but
not three months. No statistically significant difference in contrast
sensitivity between treated and control groups was reported by
Marcus 2001.
Quality of life outcomes were reported in SFRADS 2002. Visual
functioning was assessed by the Daily Living Tasks Dependent on
Vision (DLTV) questionnaire (Hart 1999). There were no differ-
ences between treatment and control groups on any dimension of
the DLTV 12 or 24 months after treatment.
Adverse effects
The incidence of adverse events was low in all the trials reviewed.
Three trials found slightly higher rates of cataract progression in
the treatment groups but this was not statistically significant (
Kobayashi 2000; Marcus 2001; RAD 1999).
There were no reported cases of radiation retinopathy, optic neu-
ropathy or the development of malignancy. However, the duration
of follow-up was likely to be too short to detect this. Given the
mean age of participants this may not be a major concern.
Although there was an overall beneficial effect for treatment with
regard to vision, Bergink 1998 reported a drop in central vision
with a loss of 3 or more lines in a substantial proportion of pa-
tients in the treatment group. This was not reported by trials using
standard fractions (2 Gy) in the treatment protocol.
Other complications reported in the treatment group included
one case of rhegmatogenous retinal detachment and one case of
a large non-clearing vitreous haemorrhage (Marcus 2001); tran-
sient conjunctival injection in two participants (Kobayashi 2000);
and transient disturbance of the precorneal tear film, found to be
significant (SFRADS 2002).
D I S C U S S I O N
Summary of main results
We identified 14 trials of the effect of radiotherapy on neovas-
cular AMD, which randomised 1242 participants. One of these
trials studied plaque brachytherapy, the rest external beam radio-
therapy. Not all of these trials could be included in each of our
planned analyses because of differences in the way outcomes were
presented and follow-up times. Summary of findings for the main
comparison summarises the effects of radiotherapy on visual loss
at 12months follow-up. Overall the quality of the evidence ranged
from low to moderate. There was some evidence for an effect of
radiotherapy on severe visual acuity loss (loss of 6+ lines) over 12
months with a statistically significant 40% relative risk reduction.
However, this effect was not seen for more moderate visual loss
(loss of 3+ lines) and was not maintained at 24 months. However,
it must be noted that different trials contribute to these analyses.
However, when repeating the analyses for 6+ lines using only three
trials that had data for 12 and 24 months a similar pattern was
observed.
There was considerable clinical and statistical inconsistency be-
tween trials. Most trials found effects that favoured treatment, but
these were not always significant. The exception wasMarcus 2001
which consistently found non-significant effects that favoured the
control group. It is difficult to ascertain why this trial should be
different but it had sham irradiation in the control group and a
very low percentage of participants with classic CNV (12%).
With only 14 trials in the review and differences between trials in
terms of outcome reporting it was difficult to explore the sources
of heterogeneity. Subgroup analyses comparing groups of trials
with different attributes (i.e. low versus high dosage; low versus
high percentage with classic CNV; and sham irradiation versus
observation of the control group) did not reveal any statistically
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significant interactions. With small numbers of trials in each sub-
group (range three to five) this was not surprising.
It is encouraging that therewere no significant adverse effects noted
with up to 20 Gy of radiotherapy deployed in 2 Gy fractions. The
occurrence of severe visual loss in some treated patients receiving
24 Gy in larger fractions questions the safety of higher doses.
Higher doses of radiation are associated with greater morbidity
such as radiation retinopathy and optic neuropathy. Given the
lack of a clear benefit of higher doses it cannot be assumed that
these may be used safely in clinical practice. The long-term risk to
the fellow eye from collateral radiation exposure also needs to be
determined.
Neovascular AMD is a heterogenous disease with variation in
CNV composition and disease presentation. Differences in lesion
composition, size and time in the natural history at presentation
may be a source of variability when assessing treatment outcome
among the different trials. Evidence from the TAP (TAP Study
1999) and VIP (Bressler 2002) trials showed that many people
with minimally classic (less than 50% classic) and occult with no
classic lesions had relatively good natural history. Despite present-
ing as large lesions, they maintained reasonably good visual acuity
throughout 24 months follow up without treatment. In contrast,
the majority of predominantly classic (more than 50% classic) le-
sions were four disc areas or less and were more likely to present
with lower visual acuity.
Kobayashi 2000 found a significant treatment benefit in partici-
pants with smaller CNV (less than 1.5mm2) with regard to smaller
increase in lesion size and significantly smaller decrease in Log-
MAR visual acuity for over two years. They also found that there
was no significant difference in visual outcome in participants with
larger CNV (more than 1.5 mm2). In contrast, Marcus 2001 did
not find lesion size (less than one to more than six disc areas) de-
termined treatment outcome.When the composition of the lesion
was considered, Bergink 1998 and Kobayashi 2000 found a better
treatment outcome for occult lesions. SFRADS 2002 suggested
that one possible reason for the negative outcome in their trial
was the predominance of wholly classic and predominantly clas-
sic subgroups. This finding was not supported by the other trials
included in this review.
Overall completeness and applicability of
evidence
Although there are 14 trials published, because of the different
dosages used, and different outcomemeasures and follow-up times
reported, the overall completeness of the evidence is less thanmight
be expected from the number of trials. It is possible that there is
an optimum treatment regime that has not yet been identified.
Quality of the evidence
The evidence was moderate to low quality depending on the out-
come (Summary of findings for the main comparison).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is possible that a moderate treatment benefit from radiotherapy
exists in terms of prevention of severe visual loss. However, con-
siderable clinical and statistical heterogeneity between published
trials makes it difficult to draw firm conclusions. It is also possible
that the moderate treatment effects seen could be explained by
biases in the way that the studies were conducted. Overall, we can
say that the results of this review do not currently support the use
of radiotherapy in people with neovascular AMD.
Implications for research
Future trials should have a sufficient sample size to detect mod-
erate effects and should report data on visual acuity outcomes so
as to enable their inclusion in systematic overviews. Consistent
reporting of data on factors such as lesion size and composition
would also facilitate synthesis. Adequate masking of the treatment
groups should be considered a priority. It is possible that radio-
therapy may have a role as adjunctive treatment in conjunction
with pharmacological treatments.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AMDLRTSG 2003
Methods 2-year prospective randomised controlled study at 18 sites in Japan
Participants People with CNV due to AMD.
Interventions 10 fractions of 2 Gy external beam radiotherapy versus observation
Outcomes Visual acuity, size of CNV.
Notes Information from trial from summary translation.
AMDRT 2004
Methods Multicentre study: 10 sites.
Randomisation stratified by lesion type (new or recurrent CNV following thermal laser
photocoagulation) and blood (< 50% or >= 50%)
Participants Country: USA.
Number randomised: 88.
New CNV arm: mean age 77 years (range 63 to 92).
Recurrent CNV arm: mean age 80 years (range 73 to 78).
58% women.
Inclusion: visual acuity of at least 20/320 and subfoveal CNV (occult CNV, minimally
classic CNV or predominantly classic CNV) with fibrosis if present comprising < 50%
of the lesion not amenable to treatment. AMD confirmed by drusen > 63 µm or focal
hyperpigmentation in either eye or evidence of CNV, geographic atrophy or serous
detachment of the pigment epithelium in the non study eye
Interventions Treatment (n=41):External beam radiotherapy 20 Gy (5 x 4 Gy) 6 mv.
Control : observation (n=25) or sham radiotherapy (n=22) depending on centre
Outcomes Primary outcome:
• loss of 3 or more lines of visual acuity.
Secondary outcomes:
• lesion size graded on fluorescein angiography.
• side effects.
Notes Age-related macular degeneration radiotherapy trial (AMDRT).
Funded by the National Eye Institute and each participating institution
Sample size 100 patients; stopped early because of a low rate of recruitment
Risk of bias
Item Authors’ judgement Description
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AMDRT 2004 (Continued)
Adequate sequence generation? Yes ”Randomised treatment assignment sched-
ules, stratified by lesion type (new or recur-
rent) and status of blood (<50% or >=50%
of the lesion) were generated for each clin-
ical site“ Page 819, methods, enrolment and
randomisation procedures, 2nd paragraph.
Allocation concealment? Yes “After required examinations and photog-
raphy were completed, an eligibility check-
list was faxed to the Coordinating Center.
The enrolling ophthalmologist and clinic
coordinator verbally confirmed eligibility
of the patient by telephone with a Co-
ordinating Center staff member. For cen-
tres performing sham radiotherapy, sealed,
black-lined security envelopes containing
a randomized assignment were provided
to the ophthalmology clinical staff. At en-
rollment, the clinic co-ordinator confirmed
with the Co-ordinating center the assign-
ment of the patient to the next sequen-
tially numbered envelope for the appropri-
ate strata. The sealed envelope was sent to
the Radiation Oncology Department and
opened by the radiation oncologist and ra-
diation physicist immediately before treat-
ment. For centers not performing sham ra-
diotherapy, the coordinator called the Co-
ordinating center to obtain the treatment
assignment” Page 819, methods, enrolment
and randomisation procedures, 1st and 2nd
paragraphs.
Blinding?
Visual acuity
No “At the outset, each center had the option
to choose sham radiotherapy or observa-
tion only as the control treatment for active
radiotherapy. Three centers chose sham ra-
diotherapy.” Page 819, methods, 1st para-
graph. “During follow-up, examiners were
masked to the patient’s treatment assign-
ment” Page 820, 1st paragraph.
It was obvious which group received radio-
therapy. Only 3 out of 10 centers chose to
perform sham radiotherapy. Only some of
the control group (22/47) received sham
radiotherapy. Visual acuity assessment was
masked to treatment group, however, it is
possible that an individual’s performance
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AMDRT 2004 (Continued)
on the visual acuity test could be influenced
by their perceptions as to which treatment
they received
Blinding?
Lesion size on fluorescein angiography
Yes “Certified photographers performed all
fundus photography and fluorescein an-
giography following SST protocols. Initial
visit photography was required within 42
days of enrollment. Expert readers at the
FPRC, masked to treatment assignment,
reviewed all baseline photographs and an-
giograms for eligibility.” Page 820, photog-
raphy and fluorescein angiography, 1st and 2
nd paragraphs.
Although the report does not explicitly
state that photograph graders were masked
to treatment assignment when considering
follow-upphotographs and angiograms it is
highly likely that theywere and it is unlikely
that a participant’s knowledge of treatment
group would influence the appearance of
photographs or fluorescein angiograms
Incomplete outcome data addressed?
All outcomes
No 31/41 (76%) in treatment group seen at 12
months; 31/47 (66%) of the control group
seen at 12 months. 12 enrolled patients
were subsequently considered ineligible; all
these patients included in the analysis. 5 pa-
tients did not get the treatment they were
assigned but were analysed in the original
group to which they were assigned.
“Among allmissed visits, themost common
reason for not completing the visit was pa-
tient refusal; other reasons were illness and
transportation problems”
The follow-up in the control group was
rather low which is why this is marked “no”
Free of selective reporting? Unclear See additional table 3.
Free of other bias? Unclear “Patient enrollment began in January 2000
with a goal of 100 patients. One center
had been conducting a single center clin-
ical trial with the same protocol and con-
sent procedures and had enrolled 23 pa-
tients before their multi-center certifica-
tion; these patients are included in the anal-
ysis. In September 2001, the Data and Sa-
fety Monitoring Committee (DSMC) rec-
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AMDRT 2004 (Continued)
ommended that recruitment be halted be-
cause of a low rate of enrollment.”Page 819,
methods, second paragraph.
Anders 1998
Methods Single centre.
Allocation: not stated.
Masking: participant - no; provider - no; outcome - no.
Exclusions after randomisation: not stated
Participants Country: Germany.
Number randomised: 76.
Mean age: 77.7.
Sex: 67% women.
Inclusion Criteria: 50+ years; visual acuity decrease (0.05 and 0.5); angiographically
proven CNV.
Exclusion criteria: previous laser photocoagulation to macula; previous radiation; other
eye disease
Interventions Treatment: 12 Gy (6 x 2 Gy).
Control: observation.
Duration: 8 days
Outcomes Visual acuity, near and distance; FFA.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported.
Allocation concealment? Unclear Not reported.
Blinding?
Visual acuity
Unclear Not reported.
Blinding?
Lesion size on fluorescein angiography
Unclear Not reported.
Incomplete outcome data addressed?
All outcomes
No 19/39 radiation group and 18/37 control
group seen at 12 months. No information
as to the reason for loss to follow-up given
Free of selective reporting? Unclear See additional table 3.
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Anders 1998 (Continued)
Free of other bias? Unclear Not enough information.
Bergink 1998
Methods Single centre.
Allocation: not stated.
Masking: participant - no; provider - no; outcome - no.
Exclusions after randomisation: 3.
Participants Country: Netherlands.
Number randomised: 74.
Mean age: 74.
Sex: 56% women.
Inclusion criteria: 55+ years; visual acuity 20/200 or better; angiographically proven
CNV; clinical signs of ARM; informed consent.
Exclusion criteria: previous laser photocoagulation to macula; radiation for ear nose and
throat or brain disease; diabetes
Interventions Treatment: 24 Gy (4 x 6 Gy).
Control: observation.
Duration: 21 days.
Outcomes Visual acuity (Snellen); Doubling of CNV size (FFA).
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “...patients were assigned randomly to ei-
ther radiation treatment or observation.”
Page 322, materials and methods.
Allocation concealment? Unclear Not reported.
Blinding?
Visual acuity
No “The patients in the control group did not
receive a sham radiation treatment” Page
322, materials and methods.
Blinding?
Lesion size on fluorescein angiography
Yes “The readers were blinded for treatment
status.” Page 322, materials and methods.
Incomplete outcome data addressed?
All outcomes
No “Initially, 74 patients were included in the
study. Of these, one died and two stopped
before the first control, one because of fear
of malignancies due to the treatment. In
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Bergink 1998 (Continued)
addition, one was excluded because of pre-
viously unnoted diabetes mellitus and two
patients showed insufficient evidence for
CNVon the angiogram later on. As a result,
68 patients, 36 in the treatment group and
32 in the observation group completed at
least 3 months/ follow-up. Twelve months
follow-up was obtained in 63 patients.”
Page 322, results.
No information on the numbers originally
randomised to treatment and control
Free of selective reporting? Unclear See additional table 3.
Free of other bias? Yes
Char 1999
Methods Single centre.
Allocation: not stated.
Masking: participant - no; provider - no; outcome - unclear (yes for FFA).
Exclusions after randomisation: not stated.
Participants Country: USA.
Number randomised: 27.
Mean age: 76.
Sex: 52% women.
Inclusion criteria: Subfoveal CNV secondary to AMD with visual acuity less than 20/
40.
Exclusion criteria:
Interventions Treatment: 7.5 Gy.
Control: observation.
Duration: one day
Outcomes Visual acuity (ETDRS chart).
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Patients were randomly assigned to either
no treatment or to treatment with....” Page
575, methods.
Allocation concealment? Unclear Not reported.
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Char 1999 (Continued)
Blinding?
Visual acuity
No “... visual acuity examination with refrac-
tion by a trained ophthalmic technician,
who was masked to the patients’ status in
the trial” Page 575, methods.
However, patients were not masked which
may influence visual acuity assessment
Blinding?
Lesion size on fluorescein angiography
Yes “Initial and serial fluorescein angiograms
were read in a masked manner by two ob-
servers....” Page 575, methods.
Lack of masking of patients is unlikely to
influence this outcome
Incomplete outcome data addressed?
All outcomes
No 27 patients were entered in the trial with a
mean follow-up of 15months (range of 7 to
32 months). In the radiation group mean
follow-up was 17 months. In the group as-
signed to observation the mean follow-up
was 16 months. In the methods it states
that patients “were followed on a 3-month
basis” however it was not clear from the
report why different patients had different
lengths of follow-up
Free of selective reporting? Unclear See additional table 3.
Free of other bias? Yes
Ciulla 2002
Methods Single centre.
Allocation: not stated.
Masking: participant - yes; provider - yes; outcome - yes.
Exclusions after randomisation: not stated.
Participants Country: USA.
Number randomised: 37.
Median age: 71.
Sex: 38% women.
Inclusion criteria: Subfoveal CNV due to AMD; visual impairment of affected eye less
than 6 months duration; best-corrected VA of affected eye < = 20/40 and > = 20/400.
Exclusion criteria: Unable to maintain steady fixation; preexisting retinal eye disease or
media opacity; no informed consent
Interventions Treatment: 16 Gy (2 x 8 Gy).
Control: sham irradiation (not described).
Duration: 2 days
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Ciulla 2002 (Continued)
Outcomes Visual acuity (ETDRS chart).
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported.
Allocation concealment? Unclear Not reported.
Blinding?
Visual acuity
Yes “Masked assessment of angiography and
analysis of visual acuity between groups
were performed” Page 905.
Although this statement is not very clear
as to whether the measurement of visual
acuity was masked as the control group
had sham irradiation we have assumed that
measurement of visual acuity was masked
Blinding?
Lesion size on fluorescein angiography
Yes “Masked assessment of angiography and
analysis of visual acuity between groups
were performed” Page 905.
Incomplete outcome data addressed?
All outcomes
No “Of the 37 subjects enrolled in this inves-
tigation [...] no data were recovered from
seven subjects owing to four baseline dis-
crepancies, one off-protocol treatment due
to equipment failure, and two discontinua-
tions before the first treatment.” Page 906.
However, no information given as to which
treatment group these exclusions belonged
to and only data for 30 patients analysed.
At 12 months, 16/20 and 7/10 patients in
treatment and control group respectively
seen. Page 906, table 1.
No reason given for loss to follow-up.
Free of selective reporting? Unclear See additional table 3.
Free of other bias? Unclear “Recruitment was halted at 37 subjects for
ethical reasons regarding randomization to
sham treatment when Foot and Drug Ad-
ministration approval of Visudyne [...] was
anticipated.” Page 905.
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Eter 2002
Methods Multicentre: 3 centres.
Allocation: central telephone; blocked by centre.
Masking: participant: no; provider: no; outcome: no.
Exclusions after randomisation: 3 treatment, 1 control.
Participants Country: Germany.
Number randomised: 45.
Median age: 74.
Sex: 53% women.
Inclusion criteria: age 45+ years; classic/occult CNV; informed consent; no prior radia-
tion treatment to head; no vascular eye disease; no prior treatment of AMD.
Exclusion criteria:
Interventions Treatment: 20 Gy (10 x 2 Gy).
Control: observation.
Duration: one week.
Outcomes Visual acuity (logarithmic chart).
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Forty-five eyes of 45 patients [...] were as-
signed randomly in a ratio of 2:1 to either
radiation treatment or observation.” Page
14, patients and methods.
Allocation concealment? Unclear Not reported.
Blinding?
Visual acuity
No Not reported. As control group was obser-
vation only assumed visual acuity assess-
ment not masked
Blinding?
Lesion size on fluorescein angiography
No Not reported. As control group was obser-
vation only assumed CNV assessment not
masked
Incomplete outcome data addressed?
All outcomes
No “Although 45 patients were randomized to
either treatment or follow-up, 27 patients
in the radiation group and 15 patients in
the control group could be enrolled in the
study. Three patients were lost to follow-
up because motivation for further exami-
nations was low and because they needed
to be accompanied by relatives due to their
age and visual acuity.” Page 14, patients and
methods.
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Eter 2002 (Continued)
However, no information given as to which
group the excluded patients belonged. No
information given as to numbers examined
at six month follow-up
Free of selective reporting? No See additional table 3.
Free of other bias? Yes
Jaakkola 2005
Methods Single centre, masked.
Participants Country : Finland.
Number randomised: 86.
Mean age: 75.5. 43 (40%) men; 52 (60%) women.
Interventions Episceral brachytherapy.
8mm diameter, 16 Gy for 54 min vs 4 mm diameter ,12.6 Gy for 11 min
Outcomes Visual acuity (ETDRS chart).
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported.
Allocation concealment? Unclear “Treatment allocation was performed by envelope randomiza-
tion within CNV categories, as described below.” Page 568,
materials and methods, study design.
Not really enough information to judge whether this was done
properly
Blinding?
Visual acuity
No “Visual acuity was measured [...] by an examiner masked
against the treatment given to the patient.” Page 569, evalua-
tions and patient follow-up.
However patients were not masked.
Blinding?
Lesion size on fluorescein angiography
Yes “The angiograms were evaluated in a masked manner....” Page
569, angiographic and clinical evaluation.
Incomplete outcome data addressed?
All outcomes
Unclear 43/43 patients in radiotherapy group seen at 12 months how-
ever it was also reported that two patients had died in the in-
terim. 39/43 patients in the control group (91%) seen at 12
months. Flow chart was confusing because at 6 months it was
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Jaakkola 2005 (Continued)
reported that four patients refused and at 12 months it was
reported one patient refused. However same numbers 39/43
seen at both time points. Page 569, figure 1.
Free of selective reporting? Unclear See additional table 3.
Free of other bias? Yes
Kacperek 2001
Methods Single centre.
Allocation: unclear.
Masking: participant - no; provider - no; outcome - no.
Exclusions after randomisation: not stated.
Participants Country: UK.
Number randomised: 66.
Mean age: 76 years.
Sex:
Inclusion criteria: Aged 50+ with subfoveal CNV (classic) and evidence of AMD e.g.
drusen, VA > 6/60.
Exclusion criteria: diabetes, severe hypertension and retinal vascular disease, myopia
Interventions Treatment: 18 Gy (4 x 4.5 Gy).
Control: observation.
Duration:4 days.
Outcomes Visual acuity.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Patients [...] were randomised to between
treatment and control”. Page 7, introduc-
tion.
Allocation concealment? Unclear Not reported.
Blinding?
Visual acuity
No No masking reported. No sham interven-
tion in the control group
Incomplete outcome data addressed?
All outcomes
No 38 patients in the treatment arm, 28 for the
control arm.
28/38 and 20/28 seen at 12 months. No
information on people not seen
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Kacperek 2001 (Continued)
Free of selective reporting? No See additional table 3.
Free of other bias? Yes
Kobayashi 2000
Methods Single centre.
Allocation: computer generated.
Masking: participant - no; provider - yes; outcome - unclear (yes for FFA).
Exclusions after randomisation: not stated.
Participants Country: Japan.
Number randomised: 101.
Mean age: 72.
Sex: 64% female.
Inclusion criteria: 60+ years; unsuitability for laser under macular photocoagulation
criteria; three or less months of new or progressive CNV; visual acuity 20/50 or worse.
Exclusion criteria: pre-existing ocular disease (glaucoma, severe myopia, chronic inflam-
mation, neoplasia); diabetes; uncontrolled hypertension; known life-threatening disease
Interventions Treatment: 20 Gy (10 x 2 Gy).
Control: observation.
Duration: 14 days.
Outcomes Visual acuity (ETDRS); area of CNV (FFA); safety.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “One eye of each of the 101 patients was
prospectively randomized to receive radio-
therapy or no treatment.” and “Within 24
hours after enrollment, the patients were
randomized by means of computer-gener-
ated numbers; patients assigned 0 received
low-dose radiotherapy and those assigned
1 received no treatment. Page 618, patients
and methods.
Allocation concealment? Yes ”The treating physician (HK) was unaware
of the patients’ randomization state“. Page
618, patients and methods.
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Kobayashi 2000 (Continued)
Blinding?
Visual acuity
No ”Assessment of outcomes, including visual
acuity, angiographic interpretation, and
assessment of complications and adverse
events, was performed in a masked fashion.
“ Page 618, patients and methods.
However, patients not masked.
Blinding?
Lesion size on fluorescein angiography
Yes ”Assessment of outcomes, including visual
acuity, angiographic interpretation, and
assessment of complications and adverse
events, was performed in a masked fashion.
“ Page 618, patients and methods.
Incomplete outcome data addressed?
All outcomes
Unclear ”The overall complete follow-up rate was
84.1% (85/101) (Table 1 and Figure 1).
there was no significant difference between
the twogroups; the complete follow-up rate
was 88.2% (45/51) and 80.0% (40/50) in
the treatment group and control group, re-
spectively. Six treated patients and 10 un-
treated patientswere not evaluated, because
five patiens died with intercurrent disease,
six patients were to ill or frail to attend, and
it was not possible to contact five patients.
Page 619, results.
Free of selective reporting? Unclear See additional table 3.
Free of other bias? Yes
Marcus 2001
Methods Single centre.
Allocation: computer generated; blocked.
Masking: participant - yes; provider - yes; outcome - yes.
Exclusions after randomisation:
not stated
Participants Country: USA.
Number randomised: 83.
Mean age: 76.
Sex: 61% female.
Inclusion criteria: active subfoveal CNV secondary AMD; >48 years of age; visual acuity
> / = 20/400; clinical and angiographic evidence of a choroidal neovascular membrane,
which is itself or its contiguous blood involving the centre of the foveal avascular zone.
Exclusion criteria: previous laser treatment; choroidal neovascularisation due to other
causes; retinal vascular diseases e.g. diabetes; previous ocular, orbital or periorbital radi-
ation; likely candidates for chemotherapeutic agents
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Marcus 2001 (Continued)
Interventions Treatment: 14 Gy (7 x 2 Gy).
Control: 1 sham treatment.
Duration: 7 working days.
Outcomes Visual acuity (ETDRS); contrast sensitivity; appearance of fundus (FFA and photogra-
phy)
Notes Patients with subfoveal choroidal neovascular membranes who were eligible for subfoveal
laser according to macular photocoagulation study guidelines were offered laser versus
radiation or observation versus radiation (this study)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “The randomization incorporated block-
ing, which is recommended any time pa-
tient recruitment extends for a long period
of time. Blocks of size 2 or 4 were assigned
randomly, and a separate random permuta-
tion was used to assign the 2 treatments to
the blocks. Page 172, patient selection, entry,
and follow-up.
Allocation concealment? No ”A randomization schedule was printed
and sent to the radiology team, how then
sequentially allocated the patients to the
sham or actual radiation treatments. Page
172, patient selection, entry, and follow-up.
Blinding?
Visual acuity
Yes “The patient, examining ophthalmologist,
and ophthalmic technician were unaware
of the assignment to observation or radia-
tion treatment groups.” Page 172, patient
selection, entry, and follow-up.
Blinding?
Lesion size on fluorescein angiography
Yes “The patient, examining ophthalmologist,
and ophthalmic technician were unaware
of the assignment to observation or radia-
tion treatment groups.” Page 172, patient
selection, entry, and follow-up.
Incomplete outcome data addressed?
All outcomes
No Radiation group n=41. 37 (90%) seen at
one year, 4 with missing data. Control n=
42. 33 (79%) seen at one year, 6 with miss-
ing data, 3 withdrawn. Page 175, table 2.
Free of selective reporting? No See additional table 3.
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Marcus 2001 (Continued)
Free of other bias? Yes
RAD 1999
Methods Multicentre: 9 centres.
Allocation: computer generated.
Masking: participant - yes; provider - yes; outcome - yes.
Exclusions after randomisation:
Participants Country: Germany.
Number randomised: 205.
Mean age: 74.
Sex: 60% female.
Inclusion criteria: 50+ years old; written informed consent; exudative AMD with sub-
foveal involvement and signs of ARM in the fellow eye; CNV 6+ disc diameters in size;
visual acuity 20/320 or better in study eye; symptoms for six months or less.
Exclusion criteria: ocular disease that could compromise the visual acuity in the study
eye; haemorrhage; previous macular photocoagulation or PDT; history of antiangiogenic
drugs
Interventions Treatment: 16 Gy (8 x 2 Gy).
Control: 8 x 0 Gy.
Duration: 10 days.
Outcomes Visual acuity (ETDRS); FFA and fundus photography.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “The randomization list was compiled gen-
erating random numbers using the sta-
tistical analysis systems SWAS, version 6.
12. ” Page 2240, Method of radiation and
sham treatment, randomization procedure
and masking
Allocation concealment? Yes “To ensure concealment, external random-
ization by telephone was performed by the
Biostatistics and Data Centre, Heidelberg,
Germany.” Page 2240, Method of radiation
and sham treatment, randomization proce-
dure and masking.
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RAD 1999 (Continued)
Blinding?
Visual acuity
Yes “Patients in the placebo group were sim-
ilarly planed and placed at the linear ac-
celerator for 8 fractions with a dose of 8
x 0Gy. The machine noise during irradi-
ation was simulated, and the technicians
were instructed not to inform the patient
about the mode of treatment. The sham
treatment method was spread out over an
identical time course as the radiation treat-
ment.” Page 2240, method of radiation ther-
apy and sham treatment.
“To ensure masking of patients and oph-
thalmologists, only the respective depart-
ments of radiation therapy were informed
about treatment allocation. ”Page 2240,
Method of radiation and sham treatment,
randomization procedure and masking.
Blinding?
Lesion size on fluorescein angiography
Yes “All angiograms were read by reviewers
masked to treatment assignments.” Page
2240, angiographic evaluation.
Incomplete outcome data addressed?
All outcomes
Unclear Radiation group 88/101 (87.1%) com-
pleted study 7 of these protocol deviations.
Sham therapy group 95/104 (91.3%) com-
pleted study. Detailed information given
on loss to follow-up. Page 2241, figure 1.
Free of selective reporting? No See additional table 3.
Free of other bias? Yes
SFRADS 2002
Methods Multicentre: 3 centres.
Allocation: central telephone; blocked by centre.
Masking: participant: no; provider: no; outcome: yes.
Exclusions after randomisation: 3 treatment, 1 control.
Participants Country: UK.
Number randomised: 203.
Mean age: 75.
Sex: 57% female.
Inclusion criteria: Aged 60+; subfoveal CNV; 20/200 or better in study eye.
Exclusion criteria: Inability to give informed consent; late leakage of indeterminate origin;
blood under geometric centre of the fovea; other ocular disease; diabetes; other trials;
prior radiotherapy
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SFRADS 2002 (Continued)
Interventions Treatment: 12 Gy (6 X 2 Gy).
Control: observation.
Duration:
Outcomes Visual acuity (ETDRS chart); near vision (Bailey-Lovie chart); radiation-associated prob-
lems
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “To ensure balance within each of the 3
centers, the randomization was blocked.”
Hart et al, top of page 1031.
Allocation concealment? Yes “The randomization code was kept at the
coordinating center (Belfast) and released
by telephone on receipt of patient details.
”Hart et al, bottom of page 1030 and top of
page 1031.
Blinding?
Visual acuity
No “The optometrists who undertook visual
assessments were unaware of the treatment
status of the patients; however, neither the
treating physicians nor the patients were
masked”.Hart et al, page 1030, patients and
methods, 2nd paragraph.
Although visual acuity assessment was
masked to treatment group, physicians and
patients were not. It is possible that an in-
dividual’s performance on the visual acuity
test could be influenced by their percep-
tions as to which treatment they received
Blinding?
Lesion size on fluorescein angiography
Unclear Outcome not reported so far.
Incomplete outcome data addressed?
All outcomes
Unclear 101 allocated to treatment 102 to obser-
vation. 93/101 and 91/100 seen at 12
months. Not very good documentation for
reasons for no follow-up
Free of selective reporting? Unclear See additional table 3.
Free of other bias? Yes
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Valmaggia 2002
Methods Single centre.
Allocation: not stated.
Masking: participant - yes; provider - yes; outcome - yes.
Exclusions after randomisation: not stated.
Participants Country: Switzerland.
Number randomised: 161.
Mean age - 75.
Sex: 58% female.
Inclusion criteria: Symptoms of reduced vision, central scotoma or metamorphopsia.
Exclusion criteria: foveal haemorrhage; severe haemorrhage impeding measurement of
CNV; PED; other ocular disease (glaucoma, severe myopia, diabetic retinopathy)
Interventions Treatment: 8 Gy (4 X 2 Gy) or 16 Gy (4 X 4 Gy).
Control: 1 Gy (4 X 0.25 Gy).
Duration: 4 days.
Outcomes Visual acuity (logMAR chart); reading ability; CNV size (FFA/indocyanine green); radi-
ation-associated side effects (ocular irritation, conjunctivitis, cataract, radiation retinopa-
thy, radiation optic neuropathy)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “The patients were stratified in four differ-
ent subgroups according to the CNV type,
size and duration of the symptoms”
“According to the stratification, patients
were randomized and treated in the De-
partment of Radiation-Oncology.” Page
522, stratification.
Allocation concealment? Unclear “The collaborators in the Department of
Ophthalmology and patients were not
aware of the applied radiation dose. Col-
leagues in the Department of Radiation-
Oncology were only informed about the
eye to be treated and the stratification code.
” Page 522, stratification.
Blinding?
Visual acuity
Yes “The collaborators in the Department of
Ophthalmology and patients were not
aware of the applied radiation dose.” Page
522, stratification.
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Valmaggia 2002 (Continued)
Blinding?
Lesion size on fluorescein angiography
Yes “The collaborators in the Department of
Ophthalmology and patients were not
aware of the applied radiation dose.” Page
522, stratification.
Incomplete outcome data addressed?
All outcomes
Unclear Control group 44/52 (85%) seen at 12
months; 8Gy group 52/57 (91%) seen at
12 months; 16Gy group 43 (83%) seen at
12 months. Page 524, table 2.
Free of selective reporting? Yes See additional table 3.
Free of other bias? Yes
AMD: age-related macular degeneration
ARM: age-related maculopathy
CNV: choroidal neovascularisation
ETDRS: Early Treatment of Diabetic Retinopathy Study
FFA: fundus fluorescein angiography
Gy: gray
PDT: photodynamic therapy
PED: pigment epithelial detachment
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Avila 2009 Not a randomised controlled trial.
Barak 2005 No control group.
Bergink 1995 Treatment groups probably not randomly allocated.
Brown 1997 Treatment groups allocated sequentially.
Churei 2004 Treatment groups not randomly allocated.
Eter 2001 One eye treated and fellow eye served as a control. Unclear whether first eye treated randomly
Heier 2008 Avastin but not radiotherapy allocated randomly.
Honjo 1997 Treatment groups probably not randomly allocated.
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(Continued)
Mandai 1998 Treatment groups probably not randomly allocated.
Mandai 2000 Retrospective study - groups not allocated randomly.
Marcus 2004 Non-randomised dose escalation study.
Matsuhashi 1996 Treatment groups not allocated randomly.
Matsuhashi 2000 Treatment groups not allocated randomly. Control group consisted of people who had refused radiation or laser
treatment
Postgens 1997 Retrospective study - groups not allocated randomly.
Saric 2001 Control group consisted of patients who had refused treatment
Taniguchi 1996 Treatment and control groups probably not randomly allocated
Tholen 2000 This study initially began as an RCT but the trial was stopped because of radiogenic complications in the high
dose group (36 Gy). The study was continued as a non-randomised study and the reports did not distinguish
randomised and non-randomised comparisons
Zambarakji 2006 No untreated control group.
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D A T A A N D A N A L Y S E S
Comparison 1. RADIATION THERAPY VERSUS CONTROL
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Three or more lines visual acuity
lost at 6 months
5 503 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.55, 1.03]
2 Three or more lines visual acuity
lost at 12 months
8 759 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.74, 1.10]
3 Three or more lines visual acuity
lost at 24 months
4 428 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.63, 1.03]
4 Six or more lines visual acuity
lost at 6 months
5 502 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.18, 0.94]
5 Six or more lines visual acuity
lost at 12 months
7 576 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.44, 0.87]
6 Six or more lines visual acuity
lost at 24 months
4 428 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.64, 1.03]
7 Mean and change in visual acuity
at 12 months
10 Mean Difference (Random, 95% CI) -0.10 [-0.16, -0.04]
7.1 Mean visual acuity 5 Mean Difference (Random, 95% CI) -0.16 [-0.30, -0.02]
7.2 Change in visual acuity 5 Mean Difference (Random, 95% CI) -0.08 [-0.14, -0.01]
8 Investigating heterogeneity: type
of CNV
8 759 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.09]
8.1 Classic < 50% 5 426 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.62, 1.34]
8.2 Classic 50%+ 3 333 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.45, 1.10]
9 Investigating heterogeneity:
dosage
8 759 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.09]
9.1 > 14 Gy 3 308 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.50, 1.25]
9.2 <= 14 Gy 5 451 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.56, 1.21]
10 Investigating heterogeneity:
sham irradiation in control
group
8 759 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.09]
10.1 Control group
observation only
5 419 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.49, 1.07]
10.2 Control group sham
irradiation
3 340 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.60, 1.48]
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Analysis 1.1. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 1 Three or more lines
visual acuity lost at 6 months.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 1 Three or more lines visual acuity lost at 6 months
Study or subgroup Radiation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AMDRT 2004 7/35 9/35 10.5 % 0.78 [ 0.33, 1.86 ]
Jaakkola 2005 9/42 17/41 15.1 % 0.52 [ 0.26, 1.02 ]
Marcus 2001 23/39 19/34 28.5 % 1.06 [ 0.71, 1.57 ]
SFRADS 2002 38/93 43/87 33.5 % 0.83 [ 0.60, 1.14 ]
Valmaggia 2002 7/49 17/48 12.3 % 0.40 [ 0.18, 0.88 ]
Total (95% CI) 258 245 100.0 % 0.75 [ 0.55, 1.03 ]
Total events: 84 (Radiation), 105 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.75, df = 4 (P = 0.15); I2 =41%
Test for overall effect: Z = 1.78 (P = 0.075)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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Analysis 1.2. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 2 Three or more lines
visual acuity lost at 12 months.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 2 Three or more lines visual acuity lost at 12 months
Study or subgroup Radiation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AMDRT 2004 9/31 9/31 5.5 % 1.00 [ 0.46, 2.18 ]
Bergink 1998 11/34 16/29 8.6 % 0.59 [ 0.33, 1.05 ]
Char 1999 4/14 10/13 4.5 % 0.37 [ 0.15, 0.90 ]
Jaakkola 2005 21/43 22/41 13.6 % 0.91 [ 0.60, 1.38 ]
Marcus 2001 30/37 22/33 19.8 % 1.22 [ 0.91, 1.62 ]
RAD 1999 45/88 50/95 20.2 % 0.97 [ 0.73, 1.28 ]
SFRADS 2002 53/93 52/90 22.0 % 0.99 [ 0.77, 1.27 ]
Valmaggia 2002 8/43 14/44 5.7 % 0.58 [ 0.27, 1.25 ]
Total (95% CI) 383 376 100.0 % 0.90 [ 0.74, 1.10 ]
Total events: 181 (Radiation), 195 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 12.11, df = 7 (P = 0.10); I2 =42%
Test for overall effect: Z = 1.02 (P = 0.31)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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Analysis 1.3. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 3 Three or more lines
visual acuity lost at 24 months.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 3 Three or more lines visual acuity lost at 24 months
Study or subgroup Radiation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jaakkola 2005 30/41 29/41 28.2 % 1.03 [ 0.79, 1.36 ]
Kobayashi 2000 23/45 35/40 25.6 % 0.58 [ 0.43, 0.80 ]
SFRADS 2002 61/87 71/88 35.6 % 0.87 [ 0.73, 1.03 ]
Valmaggia 2002 11/43 15/43 10.6 % 0.73 [ 0.38, 1.41 ]
Total (95% CI) 216 212 100.0 % 0.81 [ 0.63, 1.03 ]
Total events: 125 (Radiation), 150 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.06, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.69 (P = 0.091)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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Analysis 1.4. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 4 Six or more lines
visual acuity lost at 6 months.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 4 Six or more lines visual acuity lost at 6 months
Study or subgroup Radiation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AMDRT 2004 2/35 8/35 18.8 % 0.25 [ 0.06, 1.09 ]
Jaakkola 2005 1/42 7/41 12.1 % 0.14 [ 0.02, 1.08 ]
Marcus 2001 4/39 6/34 23.9 % 0.58 [ 0.18, 1.89 ]
SFRADS 2002 18/93 20/86 37.9 % 0.83 [ 0.47, 1.46 ]
Valmaggia 2002 0/49 7/48 7.2 % 0.07 [ 0.00, 1.11 ]
Total (95% CI) 258 244 100.0 % 0.41 [ 0.18, 0.94 ]
Total events: 25 (Radiation), 48 (Control)
Heterogeneity: Tau2 = 0.39; Chi2 = 7.61, df = 4 (P = 0.11); I2 =47%
Test for overall effect: Z = 2.11 (P = 0.035)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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Analysis 1.5. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 5 Six or more lines
visual acuity lost at 12 months.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 5 Six or more lines visual acuity lost at 12 months
Study or subgroup Radiation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
AMDRT 2004 4/31 6/31 7.7 % 0.67 [ 0.21, 2.13 ]
Bergink 1998 3/34 12/29 7.7 % 0.21 [ 0.07, 0.68 ]
Char 1999 4/14 7/13 10.7 % 0.53 [ 0.20, 1.40 ]
Jaakkola 2005 8/43 14/41 16.2 % 0.54 [ 0.26, 1.16 ]
Marcus 2001 11/37 8/33 15.4 % 1.23 [ 0.56, 2.68 ]
SFRADS 2002 26/93 37/90 37.7 % 0.68 [ 0.45, 1.02 ]
Valmaggia 2002 2/43 6/44 4.6 % 0.34 [ 0.07, 1.60 ]
Total (95% CI) 295 281 100.0 % 0.62 [ 0.44, 0.87 ]
Total events: 58 (Radiation), 90 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 7.21, df = 6 (P = 0.30); I2 =17%
Test for overall effect: Z = 2.77 (P = 0.0056)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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Analysis 1.6. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 6 Six or more lines
visual acuity lost at 24 months.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 6 Six or more lines visual acuity lost at 24 months
Study or subgroup Radiation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jaakkola 2005 18/41 19/41 25.4 % 0.95 [ 0.59, 1.53 ]
Kobayashi 2000 10/45 17/40 13.5 % 0.52 [ 0.27, 1.01 ]
SFRADS 2002 37/87 44/88 56.0 % 0.85 [ 0.62, 1.17 ]
Valmaggia 2002 5/43 7/43 5.1 % 0.71 [ 0.25, 2.08 ]
Total (95% CI) 216 212 100.0 % 0.81 [ 0.64, 1.03 ]
Total events: 70 (Radiation), 87 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.30, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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Analysis 1.7. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 7 Mean and change in
visual acuity at 12 months.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 7 Mean and change in visual acuity at 12 months
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 Mean visual acuity
AMDLRTSG 2003 -0.29 (0.119898) 5.6 % -0.29 [ -0.52, -0.06 ]
Anders 1998 0.02 (0.076531) 11.3 % 0.02 [ -0.13, 0.17 ]
Char 1999 -0.22 (0.244898) 1.5 % -0.22 [ -0.70, 0.26 ]
Ciulla 2002 -0.33 (0.188776) 2.5 % -0.33 [ -0.70, 0.04 ]
Kobayashi 2000 -0.17 (0.081633) 10.3 % -0.17 [ -0.33, -0.01 ]
Subtotal (95% CI) 31.1 % -0.16 [ -0.30, -0.02 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 7.12, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 2.20 (P = 0.028)
2 Change in visual acuity
Jaakkola 2005 -0.14 (0.076531) 11.3 % -0.14 [ -0.29, 0.01 ]
Marcus 2001 -0.07 (0.079082) 10.7 % -0.07 [ -0.22, 0.08 ]
RAD 1999 0.02 (0.061224) 15.0 % 0.02 [ -0.10, 0.14 ]
SFRADS 2002 -0.06 (0.055) 16.9 % -0.06 [ -0.17, 0.05 ]
Valmaggia 2002 -0.15 (0.061224) 15.0 % -0.15 [ -0.27, -0.03 ]
Subtotal (95% CI) 68.9 % -0.08 [ -0.14, -0.01 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.71, df = 4 (P = 0.32); I2 =15%
Test for overall effect: Z = 2.40 (P = 0.017)
Total (95% CI) 100.0 % -0.10 [ -0.16, -0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 12.68, df = 9 (P = 0.18); I2 =29%
Test for overall effect: Z = 3.11 (P = 0.0019)
Test for subgroup differences: Chi2 = 0.86, df = 1 (P = 0.35), I2 =0.0%
-2 -1 0 1 2
Favours experimental Favours control
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Analysis 1.8. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 8 Investigating
heterogeneity: type of CNV.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 8 Investigating heterogeneity: type of CNV
Study or subgroup Radiation Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Classic < 50%
AMDRT 2004 9/31 9/31 6.5 % 1.00 [ 0.33, 2.99 ]
Char 1999 4/14 10/13 7.5 % 0.12 [ 0.02, 0.68 ]
Jaakkola 2005 21/43 22/41 11.7 % 0.82 [ 0.35, 1.94 ]
Marcus 2001 30/37 22/33 4.4 % 2.14 [ 0.72, 6.41 ]
RAD 1999 45/88 50/95 23.8 % 0.94 [ 0.53, 1.68 ]
Subtotal (95% CI) 213 213 53.8 % 0.91 [ 0.62, 1.34 ]
Total events: 109 (Radiation), 113 (Control)
Heterogeneity: Chi2 = 7.68, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Classic 50%+
Bergink 1998 11/34 16/29 11.8 % 0.39 [ 0.14, 1.08 ]
SFRADS 2002 53/93 52/90 23.0 % 0.97 [ 0.54, 1.74 ]
Valmaggia 2002 8/43 14/44 11.4 % 0.49 [ 0.18, 1.33 ]
Subtotal (95% CI) 170 163 46.2 % 0.70 [ 0.45, 1.10 ]
Total events: 72 (Radiation), 82 (Control)
Heterogeneity: Chi2 = 2.94, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 383 376 100.0 % 0.81 [ 0.61, 1.09 ]
Total events: 181 (Radiation), 195 (Control)
Heterogeneity: Chi2 = 11.39, df = 7 (P = 0.12); I2 =39%
Test for overall effect: Z = 1.38 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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Analysis 1.9. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 9 Investigating
heterogeneity: dosage.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 9 Investigating heterogeneity: dosage
Study or subgroup Radiation Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 > 14 Gy
Bergink 1998 11/34 16/29 11.8 % 0.39 [ 0.14, 1.08 ]
AMDRT 2004 9/31 9/31 6.5 % 1.00 [ 0.33, 2.99 ]
RAD 1999 45/88 50/95 23.8 % 0.94 [ 0.53, 1.68 ]
Subtotal (95% CI) 153 155 42.0 % 0.80 [ 0.50, 1.25 ]
Total events: 65 (Radiation), 75 (Control)
Heterogeneity: Chi2 = 2.37, df = 2 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.99 (P = 0.32)
2 <= 14 Gy
Marcus 2001 30/37 22/33 4.4 % 2.14 [ 0.72, 6.41 ]
Jaakkola 2005 21/43 22/41 11.7 % 0.82 [ 0.35, 1.94 ]
SFRADS 2002 53/93 52/90 23.0 % 0.97 [ 0.54, 1.74 ]
Valmaggia 2002 8/43 14/44 11.4 % 0.49 [ 0.18, 1.33 ]
Char 1999 4/14 10/13 7.5 % 0.12 [ 0.02, 0.68 ]
Subtotal (95% CI) 230 221 58.0 % 0.83 [ 0.56, 1.21 ]
Total events: 116 (Radiation), 120 (Control)
Heterogeneity: Chi2 = 9.00, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 383 376 100.0 % 0.81 [ 0.61, 1.09 ]
Total events: 181 (Radiation), 195 (Control)
Heterogeneity: Chi2 = 11.39, df = 7 (P = 0.12); I2 =39%
Test for overall effect: Z = 1.38 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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Analysis 1.10. Comparison 1 RADIATION THERAPY VERSUS CONTROL, Outcome 10 Investigating
heterogeneity: sham irradiation in control group.
Review: Radiotherapy for neovascular age-related macular degeneration
Comparison: 1 RADIATION THERAPY VERSUS CONTROL
Outcome: 10 Investigating heterogeneity: sham irradiation in control group
Study or subgroup Radiation Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Control group observation only
AMDRT 2004 9/31 9/31 6.5 % 1.00 [ 0.33, 2.99 ]
Bergink 1998 11/34 16/29 11.8 % 0.39 [ 0.14, 1.08 ]
Char 1999 4/14 10/13 7.5 % 0.12 [ 0.02, 0.68 ]
Jaakkola 2005 21/43 22/41 11.7 % 0.82 [ 0.35, 1.94 ]
SFRADS 2002 53/93 52/90 23.0 % 0.97 [ 0.54, 1.74 ]
Subtotal (95% CI) 215 204 60.4 % 0.73 [ 0.49, 1.07 ]
Total events: 98 (Radiation), 109 (Control)
Heterogeneity: Chi2 = 6.90, df = 4 (P = 0.14); I2 =42%
Test for overall effect: Z = 1.62 (P = 0.11)
2 Control group sham irradiation
Marcus 2001 30/37 22/33 4.4 % 2.14 [ 0.72, 6.41 ]
RAD 1999 45/88 50/95 23.8 % 0.94 [ 0.53, 1.68 ]
Valmaggia 2002 8/43 14/44 11.4 % 0.49 [ 0.18, 1.33 ]
Subtotal (95% CI) 168 172 39.6 % 0.95 [ 0.60, 1.48 ]
Total events: 83 (Radiation), 86 (Control)
Heterogeneity: Chi2 = 3.82, df = 2 (P = 0.15); I2 =48%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 383 376 100.0 % 0.81 [ 0.61, 1.09 ]
Total events: 181 (Radiation), 195 (Control)
Heterogeneity: Chi2 = 11.39, df = 7 (P = 0.12); I2 =39%
Test for overall effect: Z = 1.38 (P = 0.17)
0.1 0.2 0.5 1 2 5 10
Favours radiation Favours control
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A D D I T I O N A L T A B L E S
Table 1. External beam radiotherapy dosage
Study Total dose (Gy) Number of fractions Fraction size (Gy) Control
Bergink 1998 24 4 6 Observation
AMDRT 2004 20 5 4 Observation and sham radiotherapy
Eter 2002 20 10 2 Observation
Kobayashi 2000 20 10 2 Observation
AMDLRTSG 2003 20 10 2 Observation
Kacperek 2001 18 4 4.5 Observation
Ciulla 2002 16 2 8 Sham irradiation
RAD 1999 16 8 2 Sham irradiation (0 Gy)
Marcus 2001 14 7 2 Sham irradiation
SFRADS 2002 12 6 2 Observation
Anders 1998 12 6 2 Observation
Valmaggia 2002 8 4 2 Low dose irradiation (1 Gy)
Char 1999 7.5 1 7.5 Observation
Only one trial - Jaakkola 2005 - used plaque brachytherapy. One plaque delivered a dose of 15 Gy at a depth of 1.75 mm for 54 minutes
but as this took too long another plaque was used which delivered a dose of 12.6 Gy at 4 mm depth for 11 minutes.
Table 2. Type of choroidal neovascularisation
Study % classic % occult % mixed
AMDLRTSG No information
AMDRT 2004 17.5 (predominantly classic) 21.3 (occult only) 61.3 (minimally classic)
Anders 1998 No information
Bergink 1998 51.5 23.5 25
Char 1999 48.1 51.9
Ciulla 2002 46.4 14.3 39.3
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Table 2. Type of choroidal neovascularisation (Continued)
Eter 2002 37.0 Mixed/occult = 63.0
Jaakkola 2005 40 (“a classic component” 52 (“occult no classic”)
Kacperek 2001 No information
Kobayashi 2000 50.5 12.9 20.8
Marcus 2001 12.0 42.2 43.4
RAD 1999 37.7 62.3
SFRADS 2002 52.3 1.5 43.2
Valmaggia 2002 57.1 42.9
Table 3. Follow-up at 6 months
Study Radiotherapy group Control group
Randomised Number seen at
six months
% seen at six
months
Randomised Number seen at
six months
% seen at six
months
AMDLRTSG
2003*
38 37 97% 31 28 90%
AMDRT 2004 41 35 85% 47 35 74%
Jaakkola 2005 43 42 98% 45 41 91%
Marcus 2001 41 39 95% 42 34 81%
SFRADS 2002 99 93 94% 100 87 87%
Valmaggia 2002 52 49 94% 52 48 92%
* Number of patients randomised unclear - study reports mentions 100, 70 and 69.
Table 4. Follow-up at 12 months
Study Radiotherapy group Control group
Randomised Number seen at
12 months
% seen at 12
months
Randomised Number seen at
12 months
% seen at 12
months
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Table 4. Follow-up at 12 months (Continued)
AMDLRTSG
2003
38 35 92% 31 26 84%
AMDRT 2004 41 31 76% 47 31 66%
Bergink 1998 37 34 92% 37 29 78%
Char 1999 14 14 100% 13 13 100%
Jaakkola 2005 43 43 100% 45 41 91%
Marcus 2001 41 37 90% 42 33 79%
RAD 1999 101 88 87% 104 95 91%
SFRADS 2002 99 93 94% 100 90 90%
Valmaggia 2002 52 43 83% 52 44 85%
Table 5. Follow-up at 24 months
Study Radiotherapy group Control group
Randomised Number seen at
12 months
% seen at 12
months
Randomised Number seen at
12 months
% seen at 12
months
AMDLRTSG
2003
38 30 79% 31 21 68%
Jaakkola 2005 43 41 95% 45 41 91%
Kobayashi 2000 51 45 88% 50 40 80%
SFRADS 2002 99 87 88% 100 88 88%
Valmaggia 2002 52 43 83% 52 43 83%
Table 6. Outcome reporting grid: primary outcome
6
months:
Loss of
3+ lines
6
months:
Loss of
6+ lines
6
months:
Mean
VA
6
months:
Change
in VA
12
months:
Loss of
3+ lines
12
months:
Loss of
6+ lines
12
months:
Mean
VA
12
months:
Change
in VA
24
months:
Loss of
3+ lines
24
months:
Loss of
6+ lines
24
months:
Mean
VA
24
months:
Change
in VA
AMDL-
RTSG
E E
√
E E E
√
E E E
√
E
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Table 6. Outcome reporting grid: primary outcome (Continued)
2003
AM-
DRT
2004
√ √
E E
√ √
E E H H H H
Anders
1998
E E
√
E E E
√
E E E
√
E
Bergink
1998
E E E E
√ √
E E H H H H
*Char
1999
Ciulla
2002
E E
√
E E E
√
E E E
√
E
Eter
2002
E E A E H H H H H H H H
Jaakkola
2005
√ √
E
√ √ √
E
√ √ √
E
√
Kacperek
2001
E E C E E E C E H H H H
Kobayashi
2000
E E
√ √
E E
√ √ √
(2
lines)
√ √ √
Marcus
2001
√ √
A(me-
dian)
A(me-
dian)
√ √
A(me-
dian)
A(me-
dian)
H H H H
RAD
1999
E E E E
√
E E
√
E E A A
SFRADS
2002
√ √
E
√ √ √
E
√ √ √
E
√
Val-
maggia
2002
√ √
E
√ √ √
E
√ √ √
E
√
*Char 1991: Small study of 27 patients. Individual visual acuity data at baseline and last follow-up only reported. Average follow-up 14
months, range 0 to 32 months. Data extracted for the review on mean VA and assumed related approximately to 12 month follow-
up. Other analyses e.g., of loss of 3+ lines etc theoretically possible but probably meaningless.
A: States outcome analysed but only reported the P-value > 0.05 i.e.. NS.
E: Clear that outcome was measured (for example, includes structurally related outcomes) but not necessarily analysed.
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H: Not mentioned but clinical judgement says unlikely to have been measured (adapted from list provided by Paula Williamson at
Cochrane training workshop on selective outcome reporting bias, Edinburgh March 2009).
Table 7. Stratified analyses (3 or more lines lost at 12 months)
Subgroup Subgroup Number of trials Pooled OR 95% CI *Ratio of the subgroup
odds ratios
**95% CI
1 Classic < 50% 5 0.91 0.62, 1.34
2 Classic 50%+ 3 0.70 0.45, 1.10 0.77 0.43, 1.39
1 > 14 Gy 3 0.80 0.50, 1.25
2 <= 14 Gy 5 0.83 0.56, 1.21 1.04 0.57, 1.89
1 No sham irradia-
tion
5 0.73 0.49, 1.07
2 Sham irradiation 3 0.95 0.60, 1.48 1.30 0.36, 1.34
*The log odds ratio of subgroup 1 was subtracted from the log odds ratio of subgroup 2 and the resulting figure transformed back to
the odds ratio scale.
**Calculated using the following formula for the standard error:
√
(variance (subgroup 1 log OR) + variance (subgroup 2 log OR))
where variance is the square of the standard error (Altman 2003).
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Neovascularization, Pathologic
#4 (macula* near degenerat*)
#5 (macula* near neovasc*)
#6 (retina* near degener*)
#7 (retina* near neovasc*)
#8 (choroid* near degener*)
#9 (choroid* near neovasc*)
#10 (maculopath*)
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 MeSH descriptor Radiotherapy
#13 (radiotherap* or radiat* or irradiat*)
#14 (teletherap* or tele-therap* or proton* or plaque)
#15 (external near beam)
#16 (external-beam)
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#17 (#12 OR #13 OR #14 OR #15 OR #16)
#18 (#11 AND #17)
Appendix 2. MEDLINE search strategy
1 randomized controlled trial.pt.
2 (randomized or randomised).ab,ti.
3 placebo.ab,ti.
4 dt.fs.
5 randomly.ab,ti.
6 trial.ab,ti.
7 groups.ab,ti.
8 or/1-7
9 exp animals/
10 exp humans/
11 9 not (9 and 10)
12 8 not 11
13 exp macular degeneration/
14 exp retinal degeneration/
15 exp retinal neovascularization/
16 exp choroidal neovascularization/
17 exp macula lutea/
18 (macula$ adj2 lutea).tw.
19 maculopath$.tw.
20 ((macul$ or retina$ or choroid$) adj3 degener$).tw.
21 ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
22 or/13-21
23 exp radiotherapy/
24 (radiotherap$ or radiat$ or irradiat$ or teletherap$ or proton$ or plaque).tw.
25 (external adj3 beam).tw.
26 or/23-25
27 22 and 26
28 12 and 27
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE search strategy
1 exp randomized controlled trial/
2 exp randomization/
3 exp double blind procedure/
4 exp single blind procedure/
5 random$.tw. (397882)
6 or/1-5 (453431)
7 (animal or animal experiment).sh.
8 human.sh.
9 7 and 8
10 7 not 9
11 6 not 10
12 exp clinical trial/
13 (clin$ adj3 trial$).tw.
14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15 exp placebo/
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16 placebo$.tw.
17 random$.tw.
18 exp experimental design/
19 exp crossover procedure/
20 exp control group/
21 exp latin square design/
22 or/12-21
23 22 not 10
24 23 not 11
25 exp comparative study/
26 exp evaluation/
27 exp prospective study/
28 (control$ or propspectiv$ or volunteer$).tw.
29 or/25-28
30 29 not 10
31 30 not (11 or 23)
32 11 or 24 or 31
33 exp retina macula age related degeneration/
34 exp retina degeneration/
35 exp neovascularization pathology/
36 ((macul$ or retina$ or choroid$) adj3 degener$).tw.
37 ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
38 maculopath$.tw.
39 or/33-38
40 exp radiotherapy/
41 (radiotherap$ or radiat$ or irradiat$ or teletherap$ or proton$ or plaque).tw.
42 (external adj3 beam).tw.
43 or/40-42
44 39 and 43
45 32 and 44
Appendix 4. LILACS search strategy
macula$ or retina$ or choroid$ and degenerat$ or neovasc$ and radiotherap$ or radiat$ or irradiat$ or teletherap$ or proton$ or plaque
Appendix 5. metaRegister of Controlled Trials search strategy
macular degeneration AND radiotherapy
Appendix 6. ClinicalTrials.gov search strategy
macular degeneration AND radiotherapy
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Appendix 7. Sensitivity analyses: effect of different assumptions regarding missing data on pooled
estimates
Outcome Assumption Risk ratio Lower 95% CI Upper 95% CI % change from available case analysis
Loss of 3+ lines
visual acuity at 6
months
Missing at random
(available case anal-
ysis)
0.755 0.556 1.025 0%
Odds of outcome in
not observed twice
odds of outcome in
observed
0.742 0.555 0.994 2%
Odds of outcome
in not observed half
odds of outcome in
observed
0.77 0.559 1.061 -2%
Odds of outcome in
not observed twice
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed half
odds of outcome in
observed in control
group
0.815 0.596 1.114 -8%
Odds of outcome
in not observed half
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed twice
odds of outcome in
observed in control
group
0.7 0.516 0.949 7%
Loss of 3+ lines vi-
sual acuity at 12
months
Missing at random
(available case anal-
ysis)
0.905 0.745 1.1 0%
Odds of outcome in
not observed twice
odds of outcome in
observed
0.899 0.745 1.084 1%
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(Continued)
Odds of outcome
in not observed half
odds of outcome in
observed
0.915 0.748 1.118 -1%
Odds of outcome in
not observed twice
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed half
odds of outcome in
observed in control
group
0.975 0.804 1.183 -8%
Odds of outcome
in not observed half
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed twice
odds of outcome in
observed in control
group
0.837 0.683 1.024 8%
Loss of 3+ lines vi-
sual acuity at 24
months
Missing at random
(available case anal-
ysis)
0.81 0.636 1.033 0%
Odds of outcome in
not observed twice
odds of outcome in
observed
0.817 0.649 1.028 -1%
Odds of outcome
in not observed half
odds of outcome in
observed
0.807 0.627 1.038 0%
Odds of outcome in
not observed twice
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed half
odds of outcome in
0.856 0.683 1.074 -6%
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(Continued)
observed in control
group
Odds of outcome
in not observed half
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed twice
odds of outcome in
observed in control
group
0.768 0.593 0.994 5%
Loss of 6+ lines at 6
months
Missing at random
(available case anal-
ysis)
0.423 0.191 0.934 0%
Odds of outcome in
not observed twice
odds of outcome in
observed
0.406 0.186 0.888 4%
Odds of outcome
in not observed half
odds of outcome in
observed
0.44 0.199 0.973 -4%
Odds of outcome in
not observed twice
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed half
odds of outcome in
observed in control
group
0.488 0.225 1.055 -15%
Odds of outcome
in not observed half
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed twice
odds of outcome in
observed in control
group
0.365 0.163 0.82 14%
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(Continued)
Loss of 6+ lines at 12
months
Missing at random
(available case anal-
ysis)
0.62 0.443 0.868 0%
Odds of outcome in
not observed twice
odds of outcome in
observed
0.61 0.441 0.845 2%
Odds of outcome
in not observed half
odds of outcome in
observed
0.633 0.45 0.891 -2%
Odds of outcome in
not observed twice
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed half
odds of outcome in
observed in control
group
0.683 0.481 0.97 -10%
Odds of outcome
in not observed half
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed twice
odds of outcome in
observed in control
group
0.561 0.401 0.785 10%
Loss of 6+ lines at 24
months
Missing at random
(available case anal-
ysis)
0.811 0.638 1.032 0%
Odds of outcome in
not observed twice
odds of outcome in
observed
0.812 0.644 1.023 0%
Odds of outcome
in not observed half
odds of outcome in
observed
0.815 0.637 1.042 0%
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(Continued)
Odds of outcome in
not observed twice
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed half
odds of outcome in
observed in control
group
0.89 0.701 1.13 -10%
Odds of outcome
in not observed half
odds of outcome in
observed in treat-
ment group and
odds of outcome in
not observed twice
odds of outcome in
observed in control
group
0.741 0.58 0.947 9%
Appendix 8. Sensitivity analyses: effect of different assumptions regarding missing data on effect
estimates from individual studies
Outcome Assumption Study Risk ratio Lower 95% CI Upper 95% CI % change from available
case analysis
Loss of 3+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
AMDRT 2004 0.778 0.326 1.856 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
AMDRT 2004 0.742 0.324 1.701 5%
Odds
of outcome in
not observed half
odds of outcome
in observed
AMDRT 2004 0.816 0.336 1.981 -5%
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(Continued)
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
AMDRT 2004 0.958 0.403 2.274 -23%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
AMDRT 2004 0.632 0.269 1.482 19%
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
AMDRT 2004 1 0.459 2.178 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
AMDRT 2004 0.955 0.467 1.955 5%
Odds
of outcome in
not observed half
odds of outcome
in observed
AMDRT 2004 1.047 0.466 2.351 -5%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
AMDRT 2004 1.321 0.611 2.856 -32%
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(Continued)
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
AMDRT 2004 0.757 0.355 1.613 24%
Loss of 6+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
AMDRT 2004 0.25 0.057 1.095 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
AMDRT 2004 0.244 0.057 1.037 2%
Odds
of outcome in
not observed half
odds of outcome
in observed
AMDRT 2004 0.261 0.059 1.157 -4%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
AMDRT 2004 0.318 0.073 1.383 -27%
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(Continued)
observed in con-
trol group
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
AMDRT 2004 0.2 0.046 0.867 20%
Loss of 6+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
AMDRT 2004 0.667 0.208 2.133 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
AMDRT 2004 0.644 0.213 1.946 3%
Odds
of outcome in
not observed half
odds of outcome
in observed
AMDRT 2004 0.697 0.213 2.28 -4%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
AMDRT 2004 0.934 0.296 2.949 -40%
Odds of out-
come in not ob-
AMDRT 2004 0.48 0.153 1.506 28%
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(Continued)
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
Bergink 1998 0.586 0.326 1.054 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Bergink 1998 0.575 0.328 1.007 2%
Odds
of outcome in
not observed half
odds of outcome
in observed
Bergink 1998 0.608 0.332 1.112 -4%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Bergink 1998 0.655 0.363 1.18 -12%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
Bergink 1998 0.534 0.3 0.95 9%
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(Continued)
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Loss of 6+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
Bergink 1998 0.213 0.067 0.683 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Bergink 1998 0.209 0.067 0.655 2%
Odds
of outcome in
not observed half
odds of outcome
in observed
Bergink 1998 0.223 0.069 0.721 -5%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Bergink 1998 0.247 0.077 0.791 -16%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
Bergink 1998 0.188 0.059 0.597 12%
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(Continued)
group
Loss of 3+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
Jaakkola 2005 0.517 0.261 1.024 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Jaakkola 2005 0.506 0.258 0.994 2%
Odds
of outcome in
not observed half
odds of outcome
in observed
Jaakkola 2005 0.529 0.266 1.053 -2%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Jaakkola 2005 0.542 0.273 1.076 -5%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Jaakkola 2005 0.493 0.25 0.973 5%
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
Jaakkola 2005 0.91 0.599 1.382 0%
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(Continued)
sis)
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Jaakkola 2005 0.886 0.588 1.337 3%
Odds
of outcome in
not observed half
odds of outcome
in observed
Jaakkola 2005 0.937 0.613 1.43 -3%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Jaakkola 2005 0.937 0.613 1.43 -3%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Jaakkola 2005 0.886 0.588 1.337 3%
Loss of 3+ lines
visual acuity at
24 months
Missing
at random (avail-
able case analy-
sis)
Jaakkola 2005 1.034 0.789 1.356 0%
Odds of out-
come in not ob-
served twice
Jaakkola 2005 1.026 0.79 1.334 1%
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(Continued)
odds of outcome
in observed
Odds
of outcome in
not observed half
odds of outcome
in observed
Jaakkola 2005 1.045 0.79 1.383 -1%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Jaakkola 2005 1.063 0.808 1.399 -3%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Jaakkola 2005 1.009 0.772 1.319 2%
Loss of 6+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
Jaakkola 2005 0.139 0.018 1.084 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Jaakkola 2005 0.134 0.017 1.037 4%
Odds
of outcome in
not observed half
Jaakkola 2005 0.144 0.018 1.119 -4%
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(Continued)
odds of outcome
in observed
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Jaakkola 2005 0.149 0.019 1.154 -7%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Jaakkola 2005 0.13 0.017 1.005 6%
Loss of 6+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
Jaakkola 2005 0.545 0.256 1.16 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Jaakkola 2005 0.522 0.247 1.105 4%
Odds
of outcome in
not observed half
odds of outcome
in observed
Jaakkola 2005 0.565 0.264 1.207 -4%
Odds of out-
come in not ob-
served twice
Jaakkola 2005 0.565 0.264 1.207 -4%
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odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Jaakkola 2005 0.522 0.247 1.105 4%
Loss of 6+ lines
visual acuity at
24 months
Missing
at random (avail-
able case analy-
sis)
Jaakkola 2005 0.947 0.588 1.528 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Jaakkola 2005 0.934 0.586 1.489 1%
Odds
of outcome in
not observed half
odds of outcome
in observed
Jaakkola 2005 0.961 0.592 1.562 -1%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
Jaakkola 2005 0.995 0.617 1.606 -5%
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served half odds
of outcome in
observed in con-
trol group
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Jaakkola 2005 0.902 0.562 1.448 5%
Loss of 3+ lines
visual acuity at
24 months
Missing
at random (avail-
able case analy-
sis)
Kobayashi 2000 0.584 0.429 0.795 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Kobayashi 2000 0.598 0.447 0.802 -2%
Odds
of outcome in
not observed half
odds of outcome
in observed
Kobayashi 2000 0.574 0.415 0.794 2%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Kobayashi 2000 0.62 0.458 0.84 -6%
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Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Kobayashi 2000 0.554 0.405 0.758 5%
Loss of 6+ lines
visual acuity at
24 months
Missing
at random (avail-
able case analy-
sis)
Kobayashi 2000 0.523 0.272 1.006 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Kobayashi 2000 0.52 0.277 0.975 1%
Odds
of outcome in
not observed half
odds of outcome
in observed
Kobayashi 2000 0.535 0.274 1.044 -2%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Kobayashi 2000 0.606 0.316 1.163 -16%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
Kobayashi 2000 0.459 0.24 0.876 12%
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served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Loss of 3+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
Marcus 2001 1.055 0.709 1.57 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Marcus 2001 1.014 0.696 1.478 4%
Odds
of outcome in
not observed half
odds of outcome
in observed
Marcus 2001 1.105 0.73 1.672 -5%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Marcus 2001 1.135 0.755 1.706 -8%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
Marcus 2001 0.987 0.673 1.448 6%
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outcome in ob-
served in control
group
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
Marcus 2001 1.216 0.913 1.621 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Marcus 2001 1.178 0.904 1.535 3%
Odds
of outcome in
not observed half
odds of outcome
in observed
Marcus 2001 1.265 0.927 1.727 -4%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Marcus 2001 1.298 0.959 1.757 -7%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Marcus 2001 1.148 0.873 1.51 6%
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Loss of 6+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
Marcus 2001 0.581 0.179 1.889 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Marcus 2001 0.533 0.168 1.696 8%
Odds
of outcome in
not observed half
odds of outcome
in observed
Marcus 2001 0.621 0.19 2.035 -7%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Marcus 2001 0.661 0.203 2.152 -14%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Marcus 2001 0.501 0.157 1.604 14%
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
Marcus 2001 1.226 0.562 2.677 0%
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Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Marcus 2001 1.142 0.541 2.41 7%
Odds
of outcome in
not observed half
odds of outcome
in observed
Marcus 2001 1.297 0.585 2.873 -6%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Marcus 2001 1.423 0.65 3.112 -16%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Marcus 2001 1.041 0.487 2.227 15%
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
RAD 1999 0.972 0.735 1.285 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
RAD 1999 0.986 0.754 1.288 -1%
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Odds
of outcome in
not observed half
odds of outcome
in observed
RAD 1999 0.957 0.717 1.277 2%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
RAD 1999 1.041 0.79 1.371 -7%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
RAD 1999 0.906 0.684 1.2 7%
Loss of 3+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
SFRADS 2002 0.827 0.598 1.143 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
SFRADS 2002 0.812 0.594 1.111 2%
Odds
of outcome in
not observed half
odds of outcome
in observed
SFRADS 2002 0.845 0.607 1.177 -2%
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Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
SFRADS 2002 0.886 0.64 1.227 -7%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
SFRADS 2002 0.774 0.562 1.065 6%
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
SFRADS 2002 0.986 0.768 1.266 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
SFRADS 2002 0.977 0.767 1.243 1%
Odds
of outcome in
not observed half
odds of outcome
in observed
SFRADS 2002 0.998 0.772 1.29 -1%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
SFRADS 2002 1.033 0.804 1.328 -5%
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treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
SFRADS 2002 0.943 0.737 1.208 4%
Loss of 3+ lines
visual acuity at
24 months
Missing
at random (avail-
able case analy-
sis)
SFRADS 2002 0.869 0.732 1.031 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
SFRADS 2002 0.876 0.745 1.03 -1%
Odds
of outcome in
not observed half
odds of outcome
in observed
SFRADS 2002 0.862 0.718 1.033 1%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
SFRADS 2002 0.905 0.764 1.073 -4%
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observed in con-
trol group
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
SFRADS 2002 0.834 0.701 0.993 4%
Loss of 6+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
SFRADS 2002 0.842 0.478 1.482 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
SFRADS 2002 0.81 0.466 1.41 4%
Odds
of outcome in
not observed half
odds of outcome
in observed
SFRADS 2002 0.868 0.491 1.536 -3%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
SFRADS 2002 0.929 0.528 1.635 -10%
Odds of out-
come in not ob-
SFRADS 2002 0.757 0.433 1.325 10%
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served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
SFRADS 2002 0.68 0.452 1.024 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
SFRADS 2002 0.675 0.453 1.007 1%
Odds
of outcome in
not observed half
odds of outcome
in observed
SFRADS 2002 0.688 0.455 1.042 -1%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
SFRADS 2002 0.73 0.486 1.098 -7%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
SFRADS 2002 0.636 0.424 0.955 6%
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odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Loss of 6+ lines
visual acuity at
24 months
Missing
at random (avail-
able case analy-
sis)
SFRADS 2002 0.851 0.617 1.173 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
SFRADS 2002 0.858 0.631 1.166 -1%
Odds
of outcome in
not observed half
odds of outcome
in observed
SFRADS 2002 0.847 0.608 1.179 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
SFRADS 2002 0.929 0.676 1.277 -9%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
SFRADS 2002 0.782 0.567 1.077 8%
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group
Loss of 3+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
Valmaggia 2002 0.403 0.184 0.884 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Valmaggia 2002 0.406 0.187 0.881 -1%
Odds
of outcome in
not observed half
odds of outcome
in observed
Valmaggia 2002 0.405 0.184 0.892 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Valmaggia 2002 0.434 0.199 0.948 -8%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Valmaggia 2002 0.379 0.173 0.828 6%
Loss of 3+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
Valmaggia 2002 0.585 0.273 1.251 0%
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sis)
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Valmaggia 2002 0.606 0.292 1.258 -4%
Odds
of outcome in
not observed half
odds of outcome
in observed
Valmaggia 2002 0.575 0.266 1.246 2%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Valmaggia 2002 0.698 0.33 1.474 -19%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Valmaggia 2002 0.5 0.234 1.064 15%
Loss of 3+ lines
visual acuity at
24 months
Missing
at random (avail-
able case analy-
sis)
Valmaggia 2002 0.733 0.382 1.409 0%
Odds of out-
come in not ob-
served twice
Valmaggia 2002 0.746 0.401 1.389 -2%
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odds of outcome
in observed
Odds
of outcome in
not observed half
odds of outcome
in observed
Valmaggia 2002 0.729 0.374 1.423 1%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Valmaggia 2002 0.868 0.456 1.651 -18%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Valmaggia 2002 0.627 0.328 1.198 14%
Loss of 6+ lines
visual acuity at 6
months
Missing
at random (avail-
able case analy-
sis)
Valmaggia 2002 0.065 0.004 1.113 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Valmaggia 2002 0.065 0.004 1.108 0%
Odds
of outcome in
not observed half
Valmaggia 2002 0.066 0.004 1.122 -2%
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odds of outcome
in observed
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Valmaggia 2002 0.071 0.004 1.215 -9%
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Valmaggia 2002 0.06 0.004 1.023 8%
Loss of 6+ lines
visual acuity at
12 months
Missing
at random (avail-
able case analy-
sis)
Valmaggia 2002 0.341 0.073 1.598 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Valmaggia 2002 0.354 0.077 1.62 -4%
Odds
of outcome in
not observed half
odds of outcome
in observed
Valmaggia 2002 0.336 0.071 1.586 1%
Odds of out-
come in not ob-
served twice
Valmaggia 2002 0.425 0.092 1.972 -25%
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odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served half odds
of outcome in
observed in con-
trol group
Odds of out-
come in not ob-
served half odds
of
outcome in ob-
served in treat-
ment group and
odds of outcome
in not observed
twice odds of
outcome in ob-
served in control
group
Valmaggia 2002 0.28 0.06 1.303 18%
Loss of 6+ lines
visual acuity at
24 months
Missing
at random (avail-
able case analy-
sis)
Valmaggia 2002 0.714 0.246 2.076 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed
Valmaggia 2002 0.722 0.256 2.038 -1%
Odds
of outcome in
not observed half
odds of outcome
in observed
Valmaggia 2002 0.712 0.243 2.092 0%
Odds of out-
come in not ob-
served twice
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
Valmaggia 2002 0.882 0.307 2.536 -24%
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served half odds
of outcome in
observed in con-
trol group
Odds
of outcome in
not observed half
odds of outcome
in observed in
treatment group
and odds of out-
come in not ob-
served twice
odds of outcome
in observed in
control group
Valmaggia 2002 0.584 0.202 1.682 18%
WH A T ’ S N E W
Last assessed as up-to-date: 22 March 2010.
Date Event Description
31 March 2010 New search has been performed Issue 5 2010: Updated searches yielded 3 new trials.
31 March 2010 New citation required but conclusions have not changed Review substantially updated including new assessment
of risk of bias and preparation of summary of findings
tables
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